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Osteoarthritis (OA) is the most common chronic joint disease. Although disease progression is 
usually slow, it can ultimately lead to joint failure with pain, stiffness, swelling and disability. 
Additionally, patients with OA are at significantly higher risk of developing comorbidity than 
without OA. Coexisting with comorbidity results in increased difficulties in OA management, 
reduced quality of life and increased disease burden. Up to date of this thesis, OA disease-
modifying therapy remains the greatest unmet. Hence, there is an urgency for developing an 
effective treatment to slow the disease progression and identifying modifiable risk factors for 
OA comorbidity.  
This thesis aims to use a mixed approach to investigate multiple aspects of OA, including the 
effect of vitamin D on the disease and its comorbidity and factors associated with its 
comorbidity. It is based on the Vitamin D Effects on Osteoarthritis (VIDEO) study, which is a 
randomised clinical trial and aims to examine the effects of monthly vitamin D 
supplementation over two years on knee pain and knee structural changes in symptomatic knee 
OA patients with low vitamin D levels. 413 participants (mean age: 63.2 years; 50% female) 
with symptomatic knee OA and low 25(OH)D levels (>12.5nmol/L and <60nmol/L) were 
randomised to treatment and control groups in Hobart and Melbourne. 
Chapter 4 describes the differences in disease progression and symptoms among people with 
knee OA by vitamin D status over time, which is a post hoc analysis of the original VIDEO 





tibial cartilage volume, less increase in effusion-synovitis volume and more improvement in 
knee joint physical function compared with those who did not. This suggests beneficial effects 
of maintaining vitamin D sufficiency on cartilage loss, effusion-synovitis and physical function 
in patients with symptomatic knee OA.  
Chapter 5 investigates whether vitamin D supplementation and maintaining vitamin D 
sufficiency are associated with changes in inflammatory and metabolic biomarkers over two 
years in patients with knee OA and vitamin D deficiency. Vitamin D supplementation had no 
significant effects on changes in serum hs-CRP, IL-6, IL-8, IL-10, leptin, adiponectin, resistin, 
adipsin and apelin, compared to placebo. Furthermore, being consistently vitamin D sufficient 
over two years was also not associated with changes in these biomarkers compared to not being 
consistently sufficient. These do not suggest vitamin D supplementation and maintaining 
vitamin D sufficiency may alter systemic inflammation in knee OA patients.   
Chapter 6 investigates the effect of vitamin D supplementation and maintaining vitamin D 
sufficiency on depressive symptoms in patients with knee OA patients. Depressive symptoms 
improved more in the vitamin D treatment group and the participants who maintained vitamin 
D sufficiency between month 3 and 24 over 24 months, compared to the placebo group and the 
group which did not maintain sufficient vitamin D, respectively. Although the improvement 
was small, and the clinical importance was uncertain, vitamin D supplementation and 
maintaining vitamin D sufficiency could reduce depressive symptoms in patients with knee 
OA. These suggest that vitamin D supplementation and maintaining adequate vitamin D levels 





Chapter 7 describes the temporal relationships between demographic and OA clinical factors, 
joint symptoms and depression in patients with symptomatic knee OA. The prevalence and the 
incidence of depression was 25.4% and 11.2%, respectively. The common OA risk factors such 
as higher BMI, lower education level and having two or more comorbidities were associated 
with prevalent depression and being female was associated with incident depression in knee 
OA patients. Also, higher levels of knee pain and physical dysfunction and having multi-site 
pain were associated with increased risks of both prevalent and incident depression. These 
findings provide empirical evidence that management of common OA risk factors, chronic pain 
and joint dysfunction may be beneficial for preventing and managing depression in knee OA 
patients.  
Chapter 8 investigates the effect of vitamin D supplementation and maintaining vitamin D 
sufficiency on foot pain in patients with knee OA patients. In this sample, 51.8% of participants 
reported they had foot pain in patients with knee OA and vitamin D deficiency. Foot pain 
improved more in the vitamin D treatment group and the participants who maintained vitamin 
D sufficiency between month 3 and 24 over 24 months, compared to the placebo group and the 
group which did not maintain sufficient vitamin D, respectively. These suggest that vitamin D 
supplementation and maintaining adequate vitamin D levels over 24 months had beneficial 
effects on foot pain deterioration in OA patients.  
In summary, this thesis indicates that depression and foot pain are common comorbidities in 
patients with knee OA. Management of common OA risk factors, chronic pain and joint 
dysfunction may be beneficial for the prevention and management of depression in knee OA 
patients. Maintaining vitamin D sufficiency may be beneficial on cartilage loss, effusion-





supplementation and maintaining vitamin D sufficiency may not affect systemic inflammation 
but may have beneficial effects on comorbidities including depression and foot pain in patients 
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Chapter 1 Introduction 
1.1 Overview of osteoarthritis 
Osteoarthritis (OA) is the most prevalent chronic joint disease and a major cause of joint pain, 
disability and reduced quality of life in elderly people1. In past few decades, the definition of 
OA has been changed from the degenerative disease to a progressive disease2. The 
Osteoarthritis Research Society International (OARSI) has defined OA as “a disorder involving 
movable joints characterised by cell stress and extracellular matrix degradation initiated by 
micro and macro injuries that activates maladaptive repair responses including pro-
inflammatory pathways of innate immunity”3. The most common risk factors, including 
systemic and local risk factors, are age, female sex, genetics, diet, metabolic syndrome, obesity, 
occupation and injury1. OA is not merely a process of wear and tear, but rather, an abnormal 
remodelling of whole joint structures, which are characterised by cartilage degradation, bone 
remodelling, osteophytes formation, variable degrees of inflammation of the synovium, and 
degeneration of ligaments4. Furthermore, there can also be changed in periarticular muscles, 
nerves, joint capsule, and local pad that may contribute to OA or the symptoms of OA4. 
It has been recognised that OA may develop from initial biochemical change in any of joint 
tissue to the presence of symptoms2 5. Although disease progression is usually slow, it can 
ultimately lead to joint failure with pain, stiffness, swelling and disability in a large proportion 
patients6. Joint pain is the primary clinical symptom in OA and a key determinant for seeking 
medical care. Current guidelines have addressed to relief the joint symptoms, particular in 
improved function and pain relieving7. However, there is no effective treatment existing to 
slow the structural progression. In the severe stage of disease progression, most patients are 





comorbidities8. Moreover, the presence of comorbidities in older adults with OA is associated 
with more pain, greater dysfunction, and worse prognosis and management of OA and 
contributed to substantial burdens9-11. Therefore, there is an urgency for developing effective 
treatments to slow the disease progression and comorbidity.  
1.1.1 Epidemiology of OA 
1.1.1.1 Definition  
OA definition can influence prevalence and incidence estimates12. For the epidemiologic 
investigation, OA is defined as radiographic OA (ROA), clinical OA and symptomatic OA. 
There are several radiographic scoring systems existing. Of these, the Kellgren and Lawrence 
(K&L) grade system is the most widely used to identify and assess the grade of OA13. The 
overall grades of K&L joint scoring system range from 0 to 4, and are related to osteophytes 
and joint space narrowing (JSN), as follows14:  
grade 0, none: no features of OA; 
grade 1, doubtful: questionable osteophytes or questionable JSN; 
grade 2, minimal: definitive small osteophytes, little or mild JSN; 
grade 3, moderate: definitive moderate osteophytes, JSN of at least 50%; 
grade 4, severe: joint space impaired severely, cysts and sclerosis of subchondral bone.  
The grade greater than 2 with definitive osteophyte or JSN is defined as the presence of OA15. 
The World Health Organization (WHO) adopted these criteria as the standard for 
epidemiological studies on OA. However, there is a discordance between the radiographic 
severity and symptoms; individuals with early painful OA may be free from radiographic 
changes and, vice versa16. Symptomatic and clinical OA criteria have been developed by a 
subcommittee of the American College of Rheumatology (ACR)17-19. It is generally defined by 
the presence of symptoms in a joint with OA, which is more clinically relevant compared to 
the OA. The definition of symptomatic OA is combining radiological and clinical features, 






Data from the global burden of disease (GBD) 2013 study has shown that OA affects nearly 
241 million people globally21. In addition, OA may develop in any joint, but most commonly 
affects the hands, hips and knees22. The prevalence of OA varies according to the definition of 
OA, the specific joint(s) under study, and the characteristics of the study population23. 
According to the GBD 2010 study, knee OA is a more common condition than hip OA with 
the prevalence of 3.8% (radiographically confirmed symptomatic knee OA) and 0.85% 
(radiographically confirmed symptomatic hip OA), respectively24. The prevalence increased 
consistently with age and was higher in female than male (Figure 1.1).  
 
Figure 1.1 Prevalence of knee osteoarthritis by age, sex, year and region, GBD 2010 study in 
1990 and 2010 
Source: Cross M, et al. The global burden of hip and knee osteoarthritis: estimates from the global 





Prevalence of knee OA was highest in the Asia Pacific high-income region, and the prevalence 
of hip OA was highest in the North America high-income region in 2010 (Figure 1.1). In 
Australia, approximately 2.1 million (9%) Australians report suffering OA, which is over half 
(59%) of all arthritic conditions, according to the National Health Survey (NHS) in 2014–1525. 
The prevalence increases sharply from the age of 45 years, and 1 in 5 Australians (21%) over 
the age of 45 have OA. Moreover, there has been a slight increase in the age-standardised 
prevalence of OA, from 7.5% in 2001 to 8.1% in 2014–15 (Figure 1.2)25. With increasing risk 
factors for OA, the prevalence of OA is increasing, and this increasing prevalence of OA is 
expected to continue.  The global prevalence of hip and knee OA is projected to increase as the 
population ages. 
 
Figure 1.2 Prevalence rate of OA, by sex, 2001 to 2014–15 in the Australian population 
Source: Australia Bureau of Statistic (ABS). National Health Survey: First Results, 2014–15. 2015. 
1.1.1.3 Risk factors  
OA has a multi-factorial aetiology, with different sets of risk factor26. The WHO defines risk 
factor as any attribute, characteristic or exposure of an individual that increases the likelihood 
of developing a disease. The risk factors of OA have been broadly divided into person-level 





interplay between person-level factors and joint-level factors in any given individual23. The 
person-level factors include increasing age, female sex, obesity, genetics, race/ethnicity and 
nutritional factors, which may represent genetic or sociocultural influences and result in 
susceptible individuals. The joint-level factors include occupation, physical activity, injury, 
muscle strength, alignment, leg length inequality and bone/joint morphology, which are 
reflective of mechanisms related to abnormal loading of the joints and result in susceptible 
joint26.  
When considering non-modifiable factors for OA, age and sex are the strongest predictors. OA 
is not a simple consequence of joint aging and repeated "wear and tear", but a consequence of 
cumulative exposure to various risk factors and biologic changes that occur with aging, such 
as chondrocyte senescence, loss of cartilage matrix and oxidative damage27. Furthermore, the 
basic cellular mechanisms that maintain tissue homeostasis decline with age, leading to an 
inadequate response to stress or joint injury and resultant joint tissue destruction and loss. 
Strong epidemiologic evidence links female gender to an increased risk of OA. Females having 
higher fat mass, lower muscle mass and weaker muscle may explain some of the gender 
difference in OA susceptibility. The sex endogenous hormonal factors and reproductive factors 
may also play key roles in the pathogenesis of OA with complex mechanisms, especially in 
menopause females28.  
In contrast, obesity and vitamin D deficiency are modifiable risk factors. Obesity is associated 
with increased rates of OA. For every 11 pounds of weight gain, there is a 36 per cent increased 
risk for developing OA29. The increased prevalence was attributed to biomechanical factors 
and low-level inflammation. Increasing epidemiological evidence has suggested that 
insufficient serum vitamin D status is associated with the progression of OA and worsening in 
its symptoms30. Most modifiable risk factors arise primarily because of unhealthy diets or 
lifestyle choices. Evidence has shown management of modifiable risk factors could be a key 
intervention to improve the OA. For instance, weight loss and exercise are beneficial to reduce 
pain, improve function and inhibit inflammation31. Hence, recognition of the crucial role of 
modifiable risk factor should be a priority in developing OA treatments32. In the following 






1.1.1.4 Disease burden 
OA is associated with decreased physical activity and joint instability, and is one of the leading 
causes of disability worldwide. Globally, hip and knee OA was raised as the 13th highest 
contributor to the global disability (years lived with disability, YLD) in the GBD 2013 study 
and 26th highest in the disability-adjusted life years (DALYs) in the GBD 2017 study21 33. As 
a consequence of that the GBD data only include hip and knee OA, the real global burden of 
OA is likely to be underestimated. The mean YLDs increased by 75% from 1990 to 2013, 
which was reported to be the 4th fastest increasing condition. With the aging of the population 
and the increasing rate of obesity throughout the world, the considerable burden of OA 
continues to increase, particularly in the developed country.  
OA is also associated with a particularly high economic burden, largely attributed to the 
medical costs and loss of productivity in direct and indirect cost. In the United States (US), OA 
was the second most costly health condition treated in 2013. In that year, the total national 
arthritis-attributable medical care costs and earning losses among adults with arthritis were 
$303.5 billion, $139.8 billion for medical expenditures and $163.7 billion for earning loss34. In 
Australia, there were $1.6 billion costs in OA management in the year 2008 to 2009. It was 
accounted for 29% of health-care expenditure on arthritis and other musculoskeletal conditions, 
and consisted of 77% admitted patients cost, 17% out-of-hospital cost and 6% prescription 
medication35. Therefore, the impact of OA on individuals and the health system is significant. 
Greater attention to prevention and slowing the disease progression are required.  
1.1.2 Disease progression and monitoring 
OA disease progression is typically defined as increasing structural disease severity36. Early 
identification of OA is most important to improve clinical decision-making and advance the 
understanding of disease progression and treatment options. The conventional plain 
radiographs are the most common and accessible tool to detect bony features associated with 
OA, including osteophytes, subchondral bone sclerosis and cysts18. The K&L grade, based on 
the radiographic imaging, is a widely accepted semi-quantitative scoring system to assess the 
disease stage of OA. However, the conventional radiograph imaging technique is not a 





early stage of radiographic changes that are presented on radiography, there is already 10% 
cartilage loss, and over 40% of patients have had cartilage defects (Figure 1.3)39-41.  
 
Figure 1.3 Disease progression of the knee OA 
Source: https://thumbs.dreamstime.com/z/stages-knee-osteoarthritis-oa-kellgren-lawrence-
criteria-assessment-stage-classifications-45644007.jpg 
Owing to the remarkable development of imaging technique, the magnetic resonance imaging 
(MRI) is a superior and more sensitive technique than plain radiography, which allows 
examining the whole joint structural changes, especially in the early stage (Table 1.1)42. 
Strengths of MRI include its ability to visualise individual tissue pathologies that are not 
detected on radiography, as well as the interrelationship between tissue pathologies43. MRI 
assessments are mainly classified into quantitative morphometry and semiquantitative scoring 
systems, for instance, quantitative MRI measures of cartilage morphology and the Whole-
Organ Magnetic Resonance Imaging Score (WORMS) to assess typical OA structural change 





Table 1.1 Different disease stages of OA 
Stage  Changes 
I. Initial stage 
Compositional changes: 
- Biochemical changes reflecting break down of 
cartilage matrix proteins 
- MRI-detected compositional changes reflecting 
increased water content or damage of cartilage 
matrix proteins 
II. Earlier to middle stage  
MRI-evident changes:  
- Bone expansion, attrition, and bone marrow 
lesions 
- Cartilage defects and cartilage loss 
- Meniscal tear and ligament tears 
- Synovitis 
- Periarticular cysts and bursitis  
III. Joint failure stage  
Radiographically evident changes:  
- JSN  
- Osteophytes, subchondral sclerosis, and cysts 
IV. Joint death stage 
Joint replacement 







Cartilage volume loss is the hallmark of OA. Cartilage volume as assessed by MRI is a 
reproducibly quantitative and accurate measurement (Figure 1.4)45. The loss of cartilage 
volume is associated with radiographic progression, knee pain and change in pain over times39 
46-48. MRI assessment of cartilage morphology is now recommended for the assessment of 
disease progression as an endpoint for clinical trials49 50. Cartilage defects are localized lesions 
or tears within the cartilage, which can be visualized directly from MRI (Figure 1.5)51. It was 
noted that cartilage defect may not be the same process with cartilage volume loss. It is an 
important marker of early cartilage damage and may reflect a poor capacity for cartilage repair 
or trauma. Although the scoring of cartilage defects is a semi-quantitative and cannot be 
accurate as cartilage volume loss, the progression of cartilage defects can be regarded as an 
increasing split in cartilage rather than cartilage volume loss40.  
 
Figure 1.4 Quantitative 3-dimension (3D) analysis of cartilage morphology from MRI 
 
A: Sagittal MRI of human knee obtained with a fat-suppressed sequence, femoral cartilage is 
segmented; B: 3D volume reconstruction of the femoral cartilage.  
Source: Wang YXJ,et al. Non-invasive MRI assessment of the articular cartilage in clinical studies 






Figure 1.5 Representative sagittal T1-weighted fat-suppressed 3D MRI illustrating cartilage 
defects grades 
 
A: Normal patellar cartilage but with cartilage defect of grade 1 at tibial (up arrow) and femoral 
(down arrow) sites; B: Cartilage defects of grade 2 at tibial site (up arrow), of grade 1 at 
femoral site (down arrow), and of grade 3 at patellar site (left arrow). 
Source: Cicuttini F, et al. Association of cartilage defects with loss of knee cartilage in healthy, 
middle-age adults: A prospective study. Arthritis & Rheumatism 2005;52(7):2033-39. 
 
BMLs, shown on MRI, is described as regions of an ill-defined area of signal alteration (Figure 
1.6)52. BMLs reflect a wide range of abnormalities such as abnormal trabeculae, bone marrow 
necrosis/remodelling, contusion and marrow fibrosis. A number of studies have demonstrated 
the BMLs could predict the disease progression of OA53-55. Effusion and/or synovitis are the 
hallmarks of joint inflammation and can be measured using MRI quantitatively and semi-
quantitatively56 57. The effusion-synovitis measured on MRI are inflamed synovium and 
synovial fluid58. It could occur in early-stage and late-stage of OA and is also associated with 
structural and symptomatic progression, as well as an increased risk of developing OA59-61.  
Therefore, cartilage volume loss, cartilage defects, BML and effusion-synovitis could be used 





of joint replacements41 62 63. MRI has become a valuable tool to examine the multiple tissues 
abnormalities and assess the disease progression in OA patients.  
Figure 1.6 Subchondral BMLs in OA on T1-weighted fat-suppressed image 
 
A: Tibial BML is depicted as diffuse hyperintensity (arrows); B: After intravenous gadolinium 
administration, BMLs were shown with similar extent (arrowheads).  
Source: Roemer FW, et al. MRI-detected subchondral bone marrow signal alterations of the knee 
joint: terminology, imaging appearance, relevance and radiological differential diagnosis. 






Figure 1.7 T2-weighted fat-saturation fast spin echo sagittal images for effusion-synovitis in 
different subregions 
 
A: Grade 3 effusion-synovitis in the suprapatellar pouch (arrow) and grade 1 effusion-synovitis 
in the central portion (arrowhead); B: Grade 3 effusion-synovitis around posterior cruciate 
ligament (arrow).  
Source: Wang X, et al. Association between MRI-detected knee joint regional effusion-synovitis and 
structural changes in older adults: a cohort study. Annals of the Rheumatic Diseases 2016;75(3):519. 
 
1.1.3 Management  
Joint pain is the primary clinical symptoms in OA and a key determinant for seeking medical 
care. Due to the incurable condition of OA, in the past few years, international evidence-based 
guidelines, particularly the newly released European League Against Rheumatism (EULAR) 
recommendation, have addressed to manage symptoms, in particular controlling pain and 
improving function and quality of life64-66. There is a broad spectrum of interventions is 
available including nonpharmacological approaches, pharmacological treatments and surgery. 
Optimally, patients are receiving a combination of nonpharmacological and pharmacological 





The nonpharmacological therapies comprise patient education, exercise, orthotics and weight 
management, which have shown the promising effect of symptoms improvement69. Although 
the nonpharmacological treatment has been reinforced in OA management, it is often being 
undervalued and underutilised in practice. Consensus work and surveys have highlighted the 
need for health care professionals’ training in the skills of supporting self-management and 
delivering care in line with international guideline recommendations for OA70 71. In contrast, 
pharmacological interventions are widely used to alleviate joint pain when patients seek 
medical care. The non-steroidal anti-inflammatory drugs (NSAIDs) and opioids use accounts 
for the majority of pharmacological interventions72 73. Efficacy of these medications is effective 
in pain relief and function restoration74. However, these medications have considerable adverse 
effects, particularly the elderly patients and patients with multiple comorbidities 72 75 76. 
Evidence has shown the NSAIDs use associated with fold increase in risks of myocardial 
infarction (relative risk: 1.4), acute renal failure (relative risk: 3.2), or stroke (relative risk: 1.58) 
compared with placebo77-79. The use of opioids has been shown to raise the risk of all-cause 
mortality compared with the use of NSAIDs80.  
It should be noted that these treatments are for the reduction of symptoms, and do not provide 
a disease modification for OA. Most patients in the late-stage of OA with progressive pain and 
disability are seeking surgery. As a consequence of increasing prevalence, the rate of joint 
replacement surgery has raised from recent decades. In Australia, the age-standardised rate of 
total knee and hip joint replacement surgery in hospitalisation increased by 36% and 38% from 
2005-2006 to 2015-201681. Apart from the substantial economic burden and no disease 
modification effect of joint replacement surgery, there are still limitations remaining post-
surgery82. Continuing to experience pain in the replaced joint, post-surgery mortality, infection, 
stiffness, loss function of scar tissue and other complications are needed to consider.  
There are currently no existing treatments that can slow or halt the disease progression of OA. 
Moreover, these available treatments are related to adverse events or high economic burden
Therefore, there is an urgent need for clinical studies to develop cost-effective treatments that 






1.1.4 Comorbidities  
For older adults, OA is the disease with the highest co-prevalence of other chronic diseases or 
long-term conditions8. The WHO defined this condition as “comorbidity”. Various 
epidemiological studies have demonstrated that people with OA are at significantly higher risk 
of developing comorbidity than without OA83. In Australia, 2014–15, 79% people of all ages 
with arthritis reported having at least one other chronic condition25. Over half of elderly 
patients with arthritis had hypertension, followed by chronic cardiovascular disease, 
dyslipidaemia, diabetes and mental health problems/depression84. Besides, OA co-existing 
with other musculoskeletal conditions are prevalent83. A better understanding of comorbidity 
and identifying modifiable risk factors in OA are crucial and critical areas for intervention.   
Depression is a major global public health issue and is projected to be the second leading cause 
of disease burden by the year 202085. In addition, depression is prevalent comorbidity in OA 
patients. A recent systematic review and meta-analysis reported that 19.9% of people with OA 
had depressive symptoms, which is almost twofold of the prevalence in the US general 
population, with a relative risk of depression of 1.17 in those with OA compared to those 
without86 87. Furthermore, suffering from concomitant depression in OA patients contributes to 
its increased difficulties in OA  management and disease burden9.   
Foot pain is typical and very common musculoskeletal pain, especially in older adults88-90. It 
affects nearly one in five older people in the community and people who reported knee pain 
were more likely to report foot pain91. A survey included 8990 older people reported that most 
people with knee pain had multiple joint site pain, and the severity of knee pain and related 
disability were worse in the presence of pain elsewhere92. More important, foot pain is also 
prevalent in knee OA patients93. In the OA initiative cohort study, 25% knee OA patient 
reported occurrent foot pain.  Foot pain has a significant detrimental impact on health-related 
quality of life and physical activity10 94, while foot pain coexists with knee pain leading to even 
worse physical activity and lower quality of life in knee OA patients95 96.  
In summary, comorbidities are very common in OA patients and coexisted comorbidity exerts 
significant impacts on individuals and health care systems11 97. Therefore, screening, 





1.2 Vitamin D and osteoarthritis  
Vitamin D is a group of fat-soluble secosteroid. Most foods except oily fish, cod liver oil and 
mushrooms contain little vitamin D unless fortified and few vitamin D3 can be taken from diet98. 
More than 90% of the vitamin D being synthesized in the skin for most people comes from 
casual exposure to solar ultraviolet B radiation99. Hence, vitamin D has been recognised as 
sunshine vitamin. Vitamin D originating from the diet or the skin enters the circulation and is 
metabolized to 25-hydroxyvitamin D [25(OH)D] by the 25-hydroxylase in the liver and then 
to the hormonal form 1,25-hydroxyvitamin D [1,25(OH)2D] by the 25-hydroxyvitamin D-1α-
hydroxylase in the kidney100. 25(OH)D is the major form in the circulation, which determines 
people’s vitamin D status and the 1,25(OH)2D is the active form, which is the ligand for the 
vitamin D receptor (VDR), altering the transcription rates of target genes responsible for the 
biological responses101. 
1.2.1 Importance of vitamin D  
Emerging evidence has shown the vitamin D may have a promising effect on OA and its 
comorbidities for the reason that vitamin D can exert benefits beyond the skeletal benefit. Brain, 
prostate, breast, and colon tissues, among others, as well as immune cells, have a VDR and 
respond to 1,25(OH)2D102. Similar to other steroid hormones, 1,25(OH)2D binding to the VDR 
is the initial step to activate the VDR to induce or repress the expression of genes. In addition, 
some of these tissues and cells also express the enzyme 25-hydroxyvitamin D-1α-hydroxylase 
that have the ability to produce 1,25(OH)2D103.  
The ability of 1,25(OH)2D to inhibit growth and promote differentiation of a variety of cell 
types has suggested diverse functions in preventing cancers, modulating the immune system, 
and controlling various endocrine systems101 103. This is in line with epidemiological evidence 
that vitamin D can play an important role in decreasing the risk of cancers, autoimmune 
diseases, infectious diseases, and cardiovascular disease104. Vitamin D deficiency is linked to 
increased incidence of some diseases, including colorectal cancer, type 1 diabetes, multiple 
sclerosis and hypertension105-108. Furthermore, vitamin D deficiency is also associated with OA 






1.2.2 Prevalence of vitamin D deficiency  
Vitamin D deficiency is the most common nutritional deficiency worldwide109. The 
pathogenesis of vitamin D deficiency appears to be the result of a complex interplay between 
mechanical, cellular, and biochemical forces Circulation level of 25(OH)D is recommended 
to evaluate vitamin D status110. Although vitamin D deficiency is common, there is no 
consensus to define vitamin D deficiency measured by 25(OH)D111. The Institute of Medicine 
has reviewed available literature and recommended serum 25(OH)D level of less than 50 
nmol/litre (20ng/ml) as vitamin D deficiency112.  
With the definition, it has been established that 1 billion people have vitamin D deficiency or 
insufficiency113 114. Several national cohorts have suggested the prevalence of vitamin D 
deficiency. The overall prevalence rate of vitamin D deficiency in the US was 41.6%115. In 
Canada, 57.5% of men and 60.7% of women had a level of less than 75 nmol/liter116. Nearly 
one-third of Australian adults aged than 25 years old had vitamin D deficiency and 73% 
Australian had vitamin D insufficiency based on epidemiology evidence117. Furthermore, 
vitamin D deficiency is widespread throughout the European population, 13.0% European 
individuals had serum 25(OH)D below than 30 nmol/litre and 40.4% had vitamin D 
deficiency118. Similar to OA, female, elderly people and obesity/overweight population are 
more likely to develop vitamin D deficiency119 120. 
1.2.3 Vitamin D and OA 
There is increasing evidence for a potential role of vitamin D in OA pathogenesis121. Vitamin 
D may have direct effects on chondrocytes. The chondrocytes in the articular cartilage are 
important for synthesis and repair of the extracellular matrix in cartilage122. Loss of 
homeostatic balances between the anabolic and catabolic processes in chondrocytes leads to 
the failure of articular cartilage and lead to the progression of OA123. Matrix metalloproteinases 
(MMPs) are known to be important in regulating cartilage homeostasis124. VDR has been 
demonstrated expressed in human osteoarthritic chondrocytes and more than health cartilage, 
especially the superficial zone125. The presence of VDR expression could regulate MMPs 





resulting in bone and cartilage degradation125-127. This suggested that articular cartilage is 
sensitive to the effect of vitamin D. 
Vitamin D may also exert an effect on OA through regulation of bone homeostasis between 
bone formation by osteoblasts and bone resorption by osteoclasts128 129. Alterations in the 
pathological processes in bone, including subchondral bone remodelling, increased bone 
turnover and bone expansion, which lead to the initiation and progression of OA130-132. 
Additionally, vitamin D may affect OA through inhibition of inflammation. Inflammation has 
been implicated in the pathogenesis of OA as increased inflammatory and/or metabolic 
biomarkers133 134. Vitamin D may reduce the inflammatory response through modulating 
human monocyte function or VDR signalling135-137. Hence, increased inflammation may be a 
key underlying mechanism linking vitamin D deficiency to OA, and vitamin D could modify 
OA disease progression through inhibition of inflammation. In summary, vitamin D may have 
the potential to delay the development and progression of OA. 
1.2.3.1 Evidence from prospective studies   
Although the findings from high-quality prospective studies about the association between 
vitamin D deficiency and OA were inconsistent (Table 1.2), strong evidence had suggested 
vitamin D deficiency is linked with the risks of cartilage loss, when joint space loss and change 
in cartilage volume measurement were combined, in knee OA30 138-141. In addition, there was 
evidence that low levels of 25(OH)D were associated with increased progression of ROA, but 
not incident ROA assessed by the K&L score system and change in focal cartilage defects. 
However, there are inconsistent results in the association between vitamin D deficiency and 
joint pain resulting from OA and only one cohort study supported the association between 
25(OH)D levels and the prevalence or incidence of symptomatic OA142 143. Due to vitamin D 
deficiency related to the risk of cartilage loss and progression of ROA, greater attention to the 
important role of vitamin D deficiency in OA pathogenesis is required.  
  
 









Assessment of OA Results Conclusions 
Framingham OA Study 
138 
556 70.3±4.5 57% 8 
Modified K&L score 
(0-4), JSN (0-3) and 
osteophytes (0-3) 
Low serum level 25(OH)D 
predicted loss of cartilage, as 
assessed by loss of joint space (OR: 
2.3, 95% CI: 0.9 to 5.5) and 
osteophyte growth (OR: 3.1, 95% 
CI: 1.3 to 7.5). 
Low serum levels of 
25(OH)D were 
associated with 
increased risk for 




237 71 100% 8 
Hip JSN (0-4), 
osteophytes (0-3) and a 
summary grade (0-24) 
of hip ROA 
Participants in the middle (OR: 
3.21, 95% CI: 1.06, 9.68) and 
lowest (OR: 3.34, 95% CI, 1.13, 
9.86) tertiles for 25(OH)D 
associated with increased incidence 
of hip JSN compared with 
participants in the highest tertile. 
Low serum levels of 
25(OH)D were 
associated with the 
increased incident 
changes of hip JSN. 
Framingham OA Study 
and the Boston OA of 










Modified K&L score 
(0-4), JSN (0-3) and 
osteophytes (0-3); 
No association of baseline 25(OH)D 
levels with radiographic worsening 
Vitamin D status was 








in either cohort. 25(OH)D was 
unrelated to cartilage loss. 
risk of joint space and 
cartilage loss.  
Tasmanian Older Adult 
Cohort (TASOAC) 
study140 
880 51 to 79 50% 2.9 
MRI measurement for 
cartilage volume and 
defects 
Baseline serum 25(OH)D level was 
positively associated with change in 
cartilage volume and change in 
serum 25(OH)D level was 
positively associated with change 
cartilage volume. 
Achieving vitamin D 
sufficiency may prevent 
and/or retard cartilage 
loss in knee OA. 
Rotterdam Study141 1248 66.2±6.7 58% 6.5 
K&L score (0-4), JSN 
and osteophytes 
Progressive ROA occurred more in 
participants with the lowest tertile 
against the highest tertile of vitamin 
D intake (OR: 7.7, 95% CI, 1.3, 
43.5). 25(OH)D was significantly 
related to incident JSN in subjects 
with low lumbar spine BMD at 
baseline.  
Vitamin D status seems 
to influence the 
incidence and 




805 30 to 50 55% 22 
Definite and probable 
knee and hip OA 
No significant association between 
serum 25(OH)D level and the risk 
Low level of serum 





diagnosed by a clinical 
examination or by 
physicians 
of incident knee or hip OA. 
However, the risk of low serum 
25(OH)D level increased 
significantly in winter (OR: 1.57; 
95% CI: 1.10, 2.27). 
contribute to the 
development of OA. 
Osteoarthritis Initiative 
Study145 
418 61.0±9.2 47% 2 
OARSI Atlas, JSN (0-
3), progression in JSN 
score  
Participants with low vitamin D had 
increased risk of knee OA 
progression compared with those 
with greater 25(OH)D concentration 
(OR: 2.3; 95% CI: 1.1, 4.5). 
Individuals with 
vitamin D deficiency 
have an increased risk 
of knee OA 
progression. 
OR, odds ratio; 95% CI, 95% confidence interval;  
WORMS, Whole-Organ Magnetic Resonance Imaging Score; 





1.2.3.2 Evidence from clinical trials 
There are several clinical trials that have examined the effect of vitamin D supplementation on 
OA but did not provide consistent results to suggest whether OA patients should have vitamin 
D supplementation143.  
McAlindon et al reported no effect of vitamin D supplementation (vitamin D3, 2000 IU/day 
over two years) on cartilage volume loss or knee pain in patients with knee OA 146. However, 
the major limitations of this study were small sample size (n=146), the inclusion of participants 
with both vitamin D sufficiency and insufficiency, and the inclusion of participants with severe 
disease147. Participants with sufficient vitamin D may not benefit from vitamin D 
supplementation, and patients with severe disease would not respond to any treatment147. 
Consistently, a recent trial reported that vitamin D supplementation for three years did not slow 
progression of JSN and reduce Western Ontario and McMaster Universities OA Index 
(WOMAC) pain, stiffness and function in knee OA148. In contrast, another RCT reported that 
vitamin D supplement at a high dose (60,000 IU per day for ten days followed by 60,000 IU 
once a month for a year) reduced knee pain and improved function in knee OA, but this study 
was limited by its small sample size and short follow-up period 149.  
The VIDEO study in Australia overcame the limitations of these studies and aimed to 
determine whether monthly supplementation with 50,000 IU vitamin D over 24 had beneficial 
effect on WOMAC pain and cartilage volume loss, but found largely consistent results that 
vitamin D supplementation did not have significant effects on cartilage volume loss or 
WOMAC pain in patients with knee OA150. However, in the secondary analysis, the data have 
shown that the intervention group had statistically significant improvements in visual analogue 
scale (VAS) knee pain and WOMAC function when compared with the placebo group. The 
VIDEO study also reported that compared with placebo, vitamin D supplementation 
significantly reduced MRI-measured joint effusion-synovitis in patients with symptomatic 
knee OA151. This suggests that vitamin D supplementation could have anti-inflammatory 
effects in knee OA patients. While there were 62% participants reached a higher level of 
25(OH)D (>50 nmol/l) at month 24 in the placebo group, it would dilute the beneficial effects 
of vitamin D supplementation.  
Inconsistent results of these clinical trials would be due to variations in factors such as inclusion 





outcome measures. Therefore, whether vitamin D has beneficial effects on OA and whether 
inflammation is potential mechanisms linked to vitamin D and OA need to be explored in future 
studies.   
1.2.4 Vitamin D and OA comorbidities 
Vitamin D deficiency is associated with a range of mental disorders including depression152. 
The underlying biological mechanism is not clearly understood. It has been demonstrated the 
widespread distribution of VDR and 25-hydroxyvitamin D-1α-hydroxylase in the human brain 
and suggested the potential effect of vitamin D on maintaining normal brain function153 154. 
Researches have reported low vitamin D can negatively affect growth, cellular signalling and 
neural activity, which may be an underlying mechanism that contributes to depression155. 
Vitamin D insufficiency is associated with increased inflammation, which also may play an 
important role in the mechanism for depression156 157. Furthermore, insufficient vitamin D level 
is not optimal for active serotonin synthesis and releasing, leading to the development of 
depression158.  
Evidence from observational studies have demonstrated low vitamin D concentration is 
associated with depression159. Although the biological mechanisms underlying the associations 
between vitamin D deficiency and depression are unclear, the therapeutic potential of vitamin 
D supplementation for depression has been investigated in the general population and patients 
with other chronic diseases, except for OA160. Up to now, evidence from randomised controlled 
trial  (RCT) was contradictory. Considerable heterogeneity of study characteristics and 
intervention effects among studies were observed160. Conducting trial in participants without 
depression or/and vitamin D deficiency may explain why most studies did not find clear 
benefits of vitamin D supplementation161-164. Further well-designed vitamin D supplementation 
RCTs among individuals who are both depressed and vitamin D deficient are needed.   
The emergence of experimental data suggests vitamin D may exert anatomic, hormonal, 
neurological and immunological influences on pain manifestation, thereby playing a key role 
in the aetiology and maintenance of chronic pain with complicated mechanisms165-167. Vitamin 
D can modulate neuronal excitability, influences prostaglandin, inhibits synthesis of nitric 





pathways, which are associated with chronic pain168-171. These potential mechanisms may be 
involved the vitamin D deficiency and chronic pain. However, clinical research regarding the 
relationship between vitamin D deficiency and chronic pain remained limited and did not 
provide consensus.  
Previous studies have found that low levels of vitamin D are associated with chronic pain167 172 
173, but there was only one cross-sectional cohort study to examine the association between 
vitamin D status and foot pain. The population-based study has reported lower level vitamin D 
was not related to foot pain, but back pain174. However, on account of the nature of the cross-
sectional study, the causal relationship was not sure. Also, no study has explored the effect of 
vitamin D on foot pain. Even so, vitamin D deficiency and foot pain are prevalent in OA 
patients; it is also worthwhile to examine the effect of vitamin D on foot pain in future.  
1.3 Summary  
There is clear evidence that OA is a progressive and serious disease, which is associated with 
increased risk of progressive disability and increased risk of co-occurrence of comorbidity. As 
increasing OA risk factors, including the aging population, increasing obesity rate, the 
prevalence of OA is expected to become higher.  Thus, OA has substantial impacts on 
individuals and the health system. However, currently, there is no approved treatment which 
could delay the disease progression of OA.  
Experimental and epidemiological studies have shown vitamin D deficiency is a modifiable 
risk factor for disease onset and disease progression. Given that there are inconsistent results 
from clinical trials, whether vitamin D has beneficial effects on OA and the potential 
mechanisms linked vitamin D to OA needs to be explored in future studies.   
Depression and foot pain are prevalent comorbidities in OA patients. Co-occurrence with a 
commodity in OA patients is projected to increase difficulties for management and disease 
burden. Researchers and clinicians should pay more attention to the screening, prevention and 
treatment of comorbidity in OA patients. To identify modifiable risk factors systemically for 





of vitamin D on OA comorbidity, few studies have been conducted in OA patients. Therefore, 





Chapter 2 Research Questions 
The background and rationale of this thesis have been reviewed in Chapter 1.  
The research questions of this thesis are summarized as follows: 
1. To examine whether maintaining sufficient serum vitamin D levels is associated with 
changes in joint structures and symptoms in patients with symptomatic knee OA and 
baseline vitamin D insufficiency over two years. 
a. Whether maintaining sufficient serum vitamin D levels has an association with joint 
structural change over two years? 
b. Whether maintaining sufficient serum vitamin D levels has an association with 
symptomatic joint change over two years? 
2. To determine whether vitamin D supplementation or variation in vitamin D status 
affected serum inflammatory and metabolic biomarkers in patients with symptomatic 
knee OA and vitamin D insufficiency over two years. 
a. Does vitamin D supplementation affect serum inflammatory and metabolic 
biomarkers over two years?  
b. Is variation in vitamin D status associated with serum inflammatory and metabolic 
biomarkers change over two years.  
3. To evaluate the effect of vitamin D supplementation and maintaining sufficient serum 
vitamin D levels on depressive symptoms in patients with symptomatic knee OA and 
vitamin D insufficiency over two years. 





b. Whether maintaining sufficient serum vitamin D levels has an association with 
depressive symptoms? 
4. To describe and explore the prevalence, incidence and potential risk factors of 
depression in patients with symptomatic knee OA.  
a. To describe demographic and clinical factors associated with the prevalence and 
incidence of depression in patients with symptomatic knee OA. 
b. To explore the temporal relationship between depression and joint symptoms in 
patients with symptomatic knee OA. 
5. To evaluate the effect of vitamin D supplementation and maintaining sufficient serum 
vitamin D levels on foot pain in patients with symptomatic knee OA and vitamin D 
insufficiency over two years. 
a. Does vitamin D supplementation have a beneficial effect on foot pain revelling? 








Chapter 3 Methodology 
All chapters are derived from analyses using the data from the Vitamin D Effect on 
Osteoarthritis (VIDEO) study, which is a randomised clinical trial and aims to examine the 
effects of vitamin D supplementation on knee pain and knee structural changes in symptomatic 
knee OA patients with low serum vitamin D levels. This chapter is to describe the VIDEO 
study. It comprises aspects of study design, participants, intervention and outcome measures, 
and the methods of statistical analyses.  
Please note that the subsequent data chapters are presented in the form in which they were 
accepted by or submitted to peer-reviewed scientific journals. Therefore, there are some 
differences in the way that are presented in those papers as compared to this overview chapter 
due to the requirements of different journals and the details required for different analyses.  
The sample sizes used in individual chapters vary for each of the research questions. Additional 
factors which are unique to each chapter are described in more detailed in the methodology 
section of each of the subsequent chapters.  
3.1 Study design, setting and ethics  
The VIDEO study is a randomised, placebo-controlled double-blind clinical trial, which was 





Recruitment methods included advertisements through the local media and community groups 
as well as liaisons with general practitioners, specialist rheumatologists, and orthopedic 
surgeons. A telephone pre-screening was conducted to inquire about knee pain status, 
comorbidities, participation in other studies, and whether the survey recipient anticipated knee 
or hip surgery within the next two years. Potentially eligible participants were subsequently 
assessed during a clinic visit that included a physical examination, knee radiography, and 
assessment of serum 25-hydroxyvitamin D levels. 
3.1.1 Participants  
Participants with symptomatic knee OA and serum 25(OH)D> 12.5 nmol/litre and < 60 
nmol/litre was recruited. The participant inclusion and exclusion criteria for the VIDEO study 
are listed following175:  
Inclusion criteria:   
1. Age 50-79 years old;  
2. Men and women with symptomatic knee OA for at least 6 months with a pain 
VAS of at least 20 mm;  
3. Meet the ACR criteria for symptomatic knee OA assessed by a rheumatologist18;  
4. Have an ACR functional class rating of I, II and III176;  
5. Have relatively good health (0-2 according to the investigators global 
assessment of disease status on a 5-point Likert scale, range 0 [very well] to 4 
[very poor]); and  
6. Have serum vitamin D level of >12.5 nmol/L and <60 nmol/L.  
7. Is able to read, speak and understand English, capable of understanding the 
study requirements and willing to co-operate with the study instructions.  
Exclusion criteria:  
1. Patients with severe radiographic knee OA (grade 3 according to Altman’s 
atlas)177 178;  






3. Any contra-indication to having an MRI.  
4. Patients with rheumatoid arthritis, psoriatic arthritis, lupus, or cancer;  
5. Patients with severe cardiac or renal function impairment  
6. Patients with hypersensitivity to vitamin D;  
7. Patients with any condition possibly affecting oral drug absorption (e.g. 
gastrectomy or clinically significant diabetic gastro-enteropathy);  
8. having significant trauma to the knees including arthroscopy or significant 
injury to ligaments or menisci of the knee within 1 year preceding the study;  
9. having anticipated need for knee or hip surgery in the next 2 years;  
10. having taken Vitamin D supplements in last 30 days;  
A total of 599 participants were screened for eligibility, and 413 participants were recruited 
from June 2010 to December 2011. Informed written consent was obtained from all participants. 
Participants were randomly allocated to either the intervention or placebo group.  














Participants were allocated to either the vitamin D or placebo arm at a ratio of 1:1 based on 
computer-generated random numbers. Allocation concealment was ensured by a centrally 
automated allocation procedure with security in place to ensure allocation data could not be 
accessed or influenced by any person from the investigative team.  
Participants, research coordinators and investigators were all blinded to treatment assignment. 
Blinding was maintained until all data were collected, cleaned, confirmed for accuracy and 
analyses of primary outcomes were performed. 
3.1.3 Sample size  
The sample size calculation was based on the Cohen formula and assumed would give 80% 
power with a 5% probability of type 1 error (α= 0.05 and β= 0.20)179.  
Data from previous studies reported that mean annual medial tibial cartilage volume loss in 
knee OA patients was 4.5%48. Monthly supplementation with 50,000 IU vitamin D would 
correct vitamin D deficiency, and this change was estimated to lead to an absolute reduction in 
medial tibial cartilage loss of 2.2% annually, which was expected to reduce 44% risk for total 
knee replacement over four years41 48 140 180. Based on these data, with 400 participants at 
baseline (200 in each group), allowing 20% dropouts, would have at least 80% power to detect 
a 2.2% between-group difference in medial tibial cartilage loss.  
Data from previous vitamin D clinical trial, it provides a standard deviation (SD) estimate of 
70.5 on the WOMAC pain scale (0 to 500)149. The minimal clinically important difference 
(MCID) for WOMAC pain was previously reported to be 16% reduction of the score from 
baseline181. The sample with 400 participants to detect a difference between groups of 20 units 






The Tasmania Health and Human Medical Research Ethics Committee (reference number 
H1040) and Monash University Human Research Ethics Committee (reference number 
CF10/1182 - 2010000616) approved the ethics of this study. 
3.1.5 Trial registration 
ClinicalTrials.gov identifier: NCT01176344 
Anzctr.org.au identifier: ACTRN12610000495022 
3.2 Intervention  
Participants were received 50,000IU (1.25mg) oral vitamin D3 capsule (cholecalciferol) 
monthly for 24 months or an identical inert placebo175. Both the vitamin D3 compound and 
placebo were prepared by and purchased from Nationwide Compounding Pharmacy, 
Melbourne, Australia. All inform participants were contacted to remind them to take their 
capsule monthly. Adherence to vitamin D capsules was calculated by recording how many 
capsules were left when the participants were asked to take the capsules with them at follow-
up visits.  
3.3 Outcomes measurement 
Primary outcome measures of the VIDEO study were changed in knee pain, assessed using the 
WOMAC score and changed in tibial cartilage volume, assessed on MRI from baseline to 
month 24. Secondary outcomes included VAS knee pain, lower limb muscle strength and other 
structural changes on MRI. A full list of outcome measures for the VIDEO study is shown in 
Table 3.1.  
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Knee pain (VAS and 
WOMAC) 
ü ü ü ü ü ü 
Knee radiograph ü      
Serum 25-(OH)D ü  ü   ü 
Serum calcium, phosphate, 
creatinine 
ü  ü    
Micro-CT (in Melbourne)  ü    ü 
DXA (in Hobart)  ü    ü 
Core musculature measure  ü   ü ü 
Lower limb muscle 
strength 
 ü ü ü ü ü 
Hand grip strength  ü ü ü ü ü 
Weight  ü ü ü ü ü 
Height  ü    ü 
Skin fold  ü    ü 
Girth measurements  ü    ü 
Upper arm pressure  ü ü ü ü ü 
Central blood pressure  ü    ü 
Ambulatory blood pressure  ü    ü 
Arterial stiffness  ü    ü 
Physical activity (IPAQ)  ü    ü 
Medications ü ü ü ü ü ü 
Sun exposure  ü  ü ü ü 
Low back pain  ü ü ü ü ü 
Foot pain  ü ü ü ü ü 
Depression  ü ü ü ü ü 
Quality of life  ü ü ü ü ü 
Cigarette smoking  ü    ü 
Previous knee injury  ü    ü 
Occupation  ü    ü 





Adverse events  ü ü ü ü ü 
If the participant withdraws after a minimum of 6 months of treatment, he/she was requested 
to have a second knee MRI (HR-pQCT or DXA) scan. 
3.3.1 Anthropometrics  
Body weight was measured to the nearest 0.1 kg (with shoes, socks, and bulky clothing 
removed) using a single pair of electronic scales (Seca Delta Model 707, Bradford, MA, USA). 
Height was measured to the nearest 0.1 cm (with shoes and socks removed) using a stadiometer. 
BMI was calculated as kg/m2.  
3.3.2 Demographic characteristics 
Age and gender were recorded at baseline. Participants filled out a questionnaire which 
collected information on education history (grade 0: less than high school, grade 1: high school 
degree and grade 2: superior than high school degree), current regular smoker (yes or no) and 
concomitant medication usage.  
3.3.3 Serum 25(OH)D levels measurement 
Serum 25(OH)D was measured at baseline, month 3 and 24 using direct competitive 
chemiluminescent immunoassays, which is an accurate and reproducible automated tool 
(DiaSorin Inc.)182. The intra-assay and inter-assay coefficients of variation were 3.2% and 6.0%, 
respectively150. The season of blood sample was recorded.  
3.3.4 Joint symptoms assessment 
Knee symptoms were assessed at baseline and months 3, 6, 12, and 24 using WOMAC and the 
VAS scale183 184. The total WOMAC score (0-2400) is the sum of subscale scores including 
pain (0-500), stiffness (0-200), and physical function (0-1700), which is a widely used 
instrument to evaluate the functional capacity in patients with OA and demonstrates high 
performance in the clinical trial. Knee pain will be assessed by both WOMAC pain with five 
subscales in 100 mm visual analog format (walking on a flat surface, going up/down stairs, at 





And knee pain in most days of the previous month was also assessed using a 100 mm VAS. 
The VAS consists of a straight line with the endpoints defining extreme limits such as “no pain 
at all” and “pain as bad as it could be”185. Participants were asked to mark his pain level on the 
line between the two endpoints. VAS has been demonstrated to be sensitive to treatment 
effects186. 
3.3.5 Joint structures assessment  
3.3.5.1 MRI detected joint structures  
MRI scans of the study knee were obtained according to a standardised protocol at baseline 
and month 24, using a 1.5 T whole-body MRI unit with a commercial transmit-receive 
extremity coil at baseline and two years. The sequences were used as follow:  
(1) T1-weighted fat saturation 3D gradient recall acquisition in the steady state, flip angle 30°, 
repetition time 31 ms, echo time 6.71 ms, field of view 16 mm, 60 partitions; 512×512 matrix; 
acquisition time 5 min 58 s. Sagittal images were obtained at a partition thickness of 1.5 mm 
and an in-plane resolution of 0.31×0.31 (512×512 pixels).  
(2) T2-weighted/proton fat saturation 3-D fast spin echo sequence, flip angle 90, repetition time 
3067 ms, echo time 112 ms, field of view 16 cm, 15 partitions, 228×256-pixel matrix; sagittal 
images were obtained at a partition thickness of 2 mm with a between-slices gap of 0.5 to 1.0 
mm.  
The image database was transferred to a computer workstation, the Osirix imaging software187 
188. MRIs were assessed by trained readers blinded to treatment allocations according to 
methods described previously175. Baseline and follow-up MRIs were scored in pairs in 
chronological order to minimise measurement error189. 
Knee tibial and patellar cartilage volumes were measured on T1-weighted MRI by a single 
trained observer using the previously described image processing techniques190. The volumes 
of individual cartilage plates (medial tibial, lateral tibial and patella) were isolated by manually 
drawing disarticulation contours around the cartilage boundaries on a section-by-section basis. 





and 1.5 mm thickness, continuous sections) for final 3D rendering using OsiriX imaging 
software (32-bit version 5.9, Pixmeo SARL). The coefficient of variation (CV) for cartilage 
volume assessment was ranged from 2.1% to 2.6%191 192.  
Knee cartilage defects were observed on T1-weighted MRI and assessed by a single trained 
observer using a modification of the Outerbridge classification system (0-4) at patella, tibial 
and femoral, with details described as following193-195: grade 0, normal cartilage; grade 1, focal 
blistering and low-signal intensity change with an intact surface and bottom; grade 2, 
irregularities on the surface or bottom and loss of thickness of less than 50%; grade 3, deep 
ulceration with loss of thickness of more than 50%; grade 4, full thickness cartilage loss with 
exposure of subchondral bone. Cartilage defects score of ³ 2 at any sites within the 
compartment was defined as the presence of cartilage defects. Intra-observer reliability was 
expressed as the intra-class correlation coefficient (ICC), which was ranged from 0.89 to 0.94 
and inter-observer reliability was ranged from 0.85 to 0.9351 190.  
Subchondral BMLs, was defined as discrete areas of increased signal adjacent to the subcortical 
bone one T2 weighted MRI. It was measured using a modification of the classification system 
of Whole-Organ Magnetic Resonance Imaging Score at tibial (lateral and medial), femoral 
(lateral and medial) and patella (lateral and medial). The tibial and femoral were divided into 
three sub-regions (anterior, central and posterior), and the tibial has one additional sub-region 
which represents the area beneath the tibial spines196.  
BMLs were graded from 0 to 3 based on the extent of sub-regional involvement:	grade 0, none; 
grade 1, £ 25% of the subregion; grade 2, 25% to 50%; and grade 3, ³ 50%. A total score of 
the tibiofemoral compartment was calculated as the total of 1  subregional scores (0- ). The 
ICC of this BMLs measurement ranged from 0.93 to 0.98, which was excellent189 197 198.  
Effusion-synovitis were assessed using T2-weighted/proton density–weighted fast spin echo 
(FSE) sequences and measured at two regions (suprapatellar pouch and other cavity), according 
to the anatomy of the knee joint synovial cavity199. The suprapatellar pouch, extending 
superiorly from the upper surface of the patellar, between the posterior suprapatellar fat pad 





area between the central femoral and tibial condyles, around the ligaments and menisci, and 
the area behind the posterior portion of each femoral condyle, inside of the joint capsule. 
Quantitative assessment of effusion-synovitis volume was measured utilising OsiriX software, 
which has been described as previously56. The volume of joint subregions was isolated from 
the total volume selecting each region of interest (ROI) according to the intra-articular fluid-
equivalent signal on a section-by-section basis and then resampled utilizing bilinear and cubic 
interpolation for final 3D rendering using OsiriX software. The total area of all ROIs in the 
same slice was summed to obtain in the suffusion-synovitis area of the slice. The ICCs was 
ranged from 0.96 to 0.97, and inter-observer reliability was ranged from 0.93 to 0.99. 
Semi-quantitative assessment of effusion-synovitis in each subregion was scored individually 
according to WORMS and was graded collectively from 0 to 3 in terms of the estimated 
maximal distention of the synovial cavity: grade 0, normal; grade 1, < 33% of maximum 
potential distention; grade 2, 33% to 66% of maximum potential distention; grade 3,  > 66% of 
maximum potential distention196. The presence of effusion-synovitis of the whole joint was 
defined as a grade of ³ 2 in any subregion151. The inter-rater reliability was ranged from 0.63 
to 0.75, and ICC was ranged from 0.60 to 0.75 in different subregions as described previously57.  
3.3.5.2 Radiography  
A standing anteroposterior semiflexed view of the studying knee with 15◦	of fixed knee flexion 
was performed in all participants. Radiographs were assessed using the atlas developed by 
Altman et al177 178. Each of the followings was assessed on a scale of 0–3 (0= normal, 1= mild 
or 1-33% abnormal, 2= moderate or 33-66% abnormal  and 3= severe or 67-100% abnormal)200: 
medial JSN, lateral JSN, medial femoral osteophytes, medial tibial osteophytes (Figure 3.2), 
lateral femoral osteophytes, and lateral tibial osteophytes. Each score was determined by 
consensus of two readers who simultaneously assessed the radiograph with immediate 
reference to the atlas. ICC ranged from 0.65– 0.85. The presence of ROA was defined as any 






Figure 3.2 Altman altas of knee joint osteophyte 
A: grade 0 normal; B: grade 1 medial tibal osteophyte; C: grade 2 medial tibal osteophyte; D: grade 3 medial tibal osteophyte 






Figure 3.3 Altman altas of knee joint space narrowing  
A: grade 0 normal; B: grade 1 medial tibiodemoral narrowing; C: grade 2 medial tibiodemoral narrowing; D: grade 3 medial tibiodemoral 
narrowing 





3.3.6 Physical activity  
Physical activity primarily was assessed using a pedometer (SW 200 Digi-Walker, Yamax 
Corporation, Tokyo, Japan), which measures vertical displacement (steps per day) at baseline 
and month 24201. Briefly, participants were instructed to wear a pedometer for seven 
consecutive days and to record the number of steps each day and the duration and type of 
physical activity for any activities in which the pedometer could not be worn (for example, 
swimming). Mean steps/day was calculated as the average of the days worn at both time 
points202.  
Physical activity was also measured using the International Physical Activity Questionnaire 
(IPAQ) short version203. It has been developed and tested for use in adults (age range of 18-65 
years)203. The PA status (insufficiently active, sufficiently active and highly active) was 
calculated according to the scoring protocol available at http://www.ipaq.ik.se.  
3.3.7 Serum inflammatory and metabolic biomarkers  
All fasting blood samples were collected at baseline and month 24. The measurements were 
performed according to the manufacturer’s instruction. Serum inflammatory biomarker levels 
of high-sensitive C-reactive protein (hs-CRP), IL-6, IL-8 and IL-10 were measured. Serum 
metabolic cytokine levels of resistin, leptin, adiponectin, adipsin and apelin-36 were measured. 
Serum hs-CRP was measured by enzyme immunoassays (IBL Inc.). Serum IL-6, IL-8, and IL-
10 were measured by Bio-plex Luminex assay kits (Bio-Rad Laboratories Inc.). Serum leptin 
and apelin-36 were measured by enzyme-linked immunosorbent assay (ELISA, Phoenix 
Pharmaceuticals Inc.). Serum adiponectin, adipsin, resistin were measured by ELISA 
(Millipore Inc.). The inter-assay and intra-assay CVs were <10% and < 15% for all 
inflammatory biomarkers.  
3.3.8 Depressive symptoms and depression assessment  
Depressive symptoms were assessed using the patient health questionnaire (PHQ-9) at baseline, 





is widely used in multipurpose diagnoses, severity measures in the clinic, as well as assessing 
depression outcomes in research204 205.  
It is a nine-item questionnaire with a score range of 0 to 27, with each item being scored from 
0  to 3 (not at all, several days, more than half days and nearly every day). Using the mental 
health professional interview as the criterion standard, PHQ-9 scores of 5-9, 10-14, 15- 20 
and >20 represent mild, moderate, moderately severe and severe depression, respectively. A 
PHQ-9 scores ≥ 10 has a sensitivity of 88% and specificity of 88% for major depression204.   
3.3.9 Foot pain assessment  
Foot pain was measured using the Manchester Foot Pain and Disability Index (MFPDI) 
questionnaire at baseline, month 3, 6, 12 and 24. The MFPDI system was developed to measure 
foot pain and disability in the elderly, observational studies and randomized controlled trials206 
207. Each item was scored from 0  to 3 (none of the time, on some days and on most days/ every 
day). The total score was calculated by summing the scores of 17 items and higher score 
indicated greater foot pain disability.  
Four subscales were calculated including functional limitation (items 2-8), pain intensity (items 
10-11, 14-17), concern about appearance (items 12-13) and activity restriction (items 1 and 
9)208.  Presence of disabling foot pain was required at least one of the ten functional limitation 
items (items 1-9,11) experienced as on ‘most/every day(s)’ in the last month, according to the 
Roddy et al study207.   
3.4 Statistical analyses  
T-tests or chi-squared tests were used to compare the difference in means or proportions as 
appropriate. Standard diagnostic checks of residuals and model fit comparisons were 
performed routinely. A p value less than 0.05 (two-tailed) was considered statistically 
significant.  
All statistical analyses were performed on Stata 12.0 for Windows (Stata Corporation, TX, 
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4.1 Introduction  
Osteoarthritis and vitamin D deficiency are very common conditions worldwide, often co-
existing, especially in the aging population121 209. Osteoarthritis is a major cause of chronic pain 
and impaired physical function in older adults and has contributed substantially to an increased 
economic burden and imposed huge challenges on health systems worldwide210 211.  
The ideal treatment for osteoarthritis is to reduce symptoms and slow disease progression.  
These may, in turn, reduce the impact of osteoarthritis on patients’ mobility and quality of life, 
with a consequent reduction in the need for the joint replacement surgery and the health care 
costs in the long term212. In experimental studies, sufficient vitamin D can protect against 
increased bone turnover and cartilage degradation213-215. While there is increasing 
epidemiological evidence suggests that insufficient serum vitamin D status is associated with 
the progression of osteoarthritis and worsening in its symptoms, the results have been 
inconsistent30.  
In the Vitamin D Effect on Osteoarthritis (VIDEO) randomised controlled trial, we reported 
that vitamin D supplementation did not prevent tibial cartilage loss or improve knee pain as 
assessed using the Western Ontario McMaster Osteoarthritis Index (WOMAC), but had 
significant but small effects on visual analog scale (VAS) knee pain, total WOMAC score and 
WOMAC function in post-hoc analyses in participants with symptomatic knee osteoarthritis 
and insufficient vitamin D levels150. Although the level of 25-hydroxyvitamin D (25(OH)D) 
increased much more in the vitamin D group (40.6 nmol/L) than in the placebo group (6.7 
nmol/L) over two years, 62% participants in the placebo group still reached a sufficient level 
of serum 25(OH)D (>50nmol/l) at month 24 (unpublished data). Thus, the high proportion of 
participants achieving sufficient 25(OH)D level in the placebo group may have masked the 
beneficial effects of vitamin D supplementation.  
Therefore, we conducted a post-hoc analysis of the VIDEO study to describe whether 
maintaining sufficient serum vitamin D levels in people with knee osteoarthritis and baseline 
vitamin D insufficiency had an association with change in knee structures and symptoms over 
two years. 




4.2 Materials and Methods  
4.2.1 Participants  
This study is a post-hoc analysis of the VIDEO study. VIDEO was a multicentre, randomized, 
double-blind, placebo-controlled clinical trial in Tasmania and Victoria, Australia, which 
aimed to evaluate the effect of vitamin D supplementation over two years on knee pain and 
knee cartilage volume in people with symptomatic knee osteoarthritis combined with low 
25(OH)D levels. Trial design, inclusion and exclusion criteria have been described in the 
published protocol175. Participants had symptomatic knee osteoarthritis (assessed using 
American College of Rheumatology, ACR criteria18) at least for 6 months and had the pain 
of >20 mm on a 100-mm VAS with low levels of 25(OH) D (between 12.5 and 60 nmol/L). 
Participants with severe radiographic changes (grade 3 of Altman and Gold Atlas178), severe 
knee pain on standing (>80mm on a 100-mm VAS), contraindications to magnetic resonance 
imaging (MRI), rheumatoid or psoriatic arthritis, lupus, cancer, severe cardiac or renal 
impairment, hypersensitivity to vitamin D, conditions affecting oral drug absorption, 
anticipated knee or hip surgery within the next 2 years, history of significant trauma of knees 
(e.g. arthroscopy or injury to ligaments or menisci within one year preceding the study) and 
history of taking vitamin D or an investigational drug within the last 30 days were excluded175. 
413 participants aged 63.2 years old were included and 340 completed the study with serum 
25(OH)D levels measured at month 3 and 24. 
4.2.2 Vitamin D measurement and groups  
Serum 25(OH)D was measured at baseline, month 3 and 24 utilizing direct competitive 
chemiluminescent immunoassays (DiaSorin Inc.). The intra-assay and inter-assay coefficients 
of variation were 3.2% and 6.0%, respectively150. Serum 25(OH)D levels of ≤50 nmol/l was 
defined as vitamin D deficient, and of >50 nmol/l defined as vitamin D sufficient111 216. 
Participants for the current analysis were classified into three groups based on the levels of 
25(OH)D at month 3 and 24: consistently insufficient (serum 25(OH)D≤50nmol/l at both 
month 3 and 24), fluctuating (serum 25(OH)D>50nmol/l at either point) and consistently 
sufficient (serum 25(OH)D>50nmol/l at both month 3 and 24) vitamin D groups. 




4.2.3 Assessment of knee structural changes 
MRI scans of the study knee were obtained according to a standardized protocol using a 1.5 T 
whole-body MRI unit with a commercial transmit-receive extremity coil at baseline and two 
years. The sequences used for cartilage volume assessment were sagittal fat-saturated T1-
weighted spoiled gradient echo. Cartilage defects, bone marrow lesions and effusion-synovitis 
volume were assessed using T2-weighted/proton density–weighted fast spin echo sequences. 
MRIs were assessed by trained readers blinded to treatment allocations according to methods 
described previously42 175 217. 
Cartilage volume was determined using the previously described image processing 
techniques175. The volumes of individual cartilage plates (medial tibial and lateral tibial) were 
isolated by manually drawing disarticulation contours around the cartilage boundaries on a 
section-by-section basis then resampled using bilinear and cubic interpolation for final three-
dimensional rendering using OsiriX imaging software (32-bit version 5.9, Pixmeo SARL). The 
coefficient of variation was 2.1% for medial tibia and 2.2% for the lateral tibia. 
Cartilage defects (0-4) were graded using a modification of the Outerbridge classification 
system at the medial tibial, medial femoral, lateral tibial, and lateral femoral sites, with details 
described in the protocol193. A total score of the tibiofemoral compartment was calculated as 
the total of 2 subregional scores (medial tibial and femoral, lateral tibial and femoral, 0-8). 
Intra-observer reliability expressed as an intra-class correlation coefficient ranged from 0.77 to 
0.94. 
Bone marrow lesions, defined as discrete areas of increased signal adjacent to the subcortical 
bone, were measured using a modification of the classification system of Whole-Organ 
Magnetic Resonance Imaging Score (0 =none, 1 ≤25% of the subregion, 2 =25%-50%, and 3≥ 
50%)217. A total score of the tibiofemoral compartment was calculated as the total of 12 
subregional scores (0-36). The intra-class correlation coefficient of this bone marrow lesions 
measurement ranged from 0.93 to 0.98. 
Effusion-synovitis volume at 4 regions (suprapatellar pouch, central portion, posterior femoral 
recess and subpopliteal recess) were isolated from the total volume selecting each region of 




interest according to the intra-articular fluid-equivalent signal on a section-by-section basis and 
then resampled by means of bilinear and cubic interpolation for final 3D rendering using OsiriX 
software218 219. The intra-class correlation coefficient was from 0.96 to 0.97.  
Change in cartilage volume and effusion-synovitis volume were calculated as follows:  
Absolute	change	(ml) = 345546	78	9457:; − =>?;5@A;	9457:;	 
Percentage	change	per	annum	(%	p. a. )
= (GH?457I;	Jℎ>AL;)/(=>?;5@A;	9457:;
∗ O@:;	H;I6;;A	2	?J>A?	@A	Q;>R) ∗ 100 
Change in cartilage defects and bone marrow lesions were calculated as follow: 
Cartilage	defects	change = Follow	up	defects − Baseline	cartilage	defects 
Bone	marrow	lesion	change
= Follow	up	bone	marrow	lesions − Baseline	bone	marrow	lesions 
4.2.4 Assessment of symptomatic changes 
Knee symptoms were assessed at baseline and months 3, 6, 12, and 24 using WOMAC and the 
VAS183 184. The total WOMAC score (0-2400) is the sum of subscale scores including pain (0-
500), stiffness (0-200), and physical function (0-1700).  
4.2.5 Anthropometrics and questionnaires 
Height was measured to the nearest 0.1 cm (with shoes removed) using a stadiometer (Leicester 
Height Measure, Invicta Plastics Ltd, Leicester, UK). Weight was measured to the nearest 0.1 
kg (with shoes and bulky clothing removed) using electronic scales (Heine S-7307, Heine, New 
Hampshire, USA). Body mass index (kg/m2) was calculated. We also recorded the use of 
nonsteroidal anti-inflammatory drugs in VIDEO study.   
4.2.6 Statistical Analysis  




The one-way ANOVA or Kruskal-Wallis rank tests were used to compare differences in 
baseline characteristics (age, sex, body mass index, cartilage volume, cartilage defects, bone 
marrow lesions, effusion-synovitis volume, VAS scores and WOMAC scores) among three 
vitamin D groups. To take into account missing data, we assumed data were missing at random 
and used a weighted estimating equation method220 221. We estimated the probability of a 
participant remaining in the study during follow-up by fitting a logistic regression model using 
the baseline characteristics age, sex, body mass index and level of 25(OH)D as predictors, for 
which complete data were available. In subsequent analyses, completed cases were weighted 
by the inverse of their estimated probabilities of being observed. Univariable and multivariable 
linear regressions were used to examine the difference in the changes in cartilage volume, 
cartilage defects, bone marrow lesions and effusion-synovitis volume between vitamin D 
groups before and after adjustment for age, sex, body mass index, change in season of blood 
sampling. The difference in changes of symptoms between different vitamin D groups was 
analysed using a repeated-measures mixed model with terms for age, sex, body mass index and 
season of blood sampling. The correlation between the repeated measures was addressed by 
using individual participant identification as a random effect. The differences between groups 
were further adjusted for use of nonsteroidal anti-inflammatory drugs. We used Stata 12.0 for 
Windows (Stata Corp LP) for all analyses. A p-value < 0.05 (two-tailed) was regarded as 
statistically significant. 
4.3 Results  
4.3.1 Participants and Groups  
413 participants (mean age 63.2 years, 50% women) with symptomatic knee osteoarthritis and 
low vitamin D levels were enrolled in the VIDEO study from June 2010 to December 2011. 
340 (82.3%) participants completed the study with 25(OH)D measurements at month 3 and 24. 
At baseline, participants who did not complete the study were more likely to be female and had 
lower tibial cartilage volume than those who completed, but there were no other significant 
differences in baseline characteristics between these groups150. Baseline characteristics of 
participants in three vitamin D status groups are showed in Table 4.1. Forty-six participants 
were classified as consistently insufficient (mean age 62.6, 52.2% females), 68 as fluctuating 
(mean age 62.9, 55.9% females) and 226 as consistently sufficient (mean age 63.5, 43.4% 




females) vitamin D groups. There were no significant differences in baseline characteristics 
among groups.    












Sex, Female, No. (%) 24 (52.2%) 38 (55.9%) 98 (43.4%) 0.15 
Age, y 62.6 (8.0) 62.9 (6.1) 63.5 (7.2) 0.68 
Body Mass Index   30.6 (4.6) 29.0 (4.5) 29.4 (4.9) 0.21 
Cartilage Volume, cm3     
Later Tibial  2.0 (0.7) 2.0 (0.6) 2.1 (0.7) 0.32 
Medial Tibial  1.4 (0.5) 1.5 (0.5) 1.6 (0.5) 0.12 
Total Tibial 3.4 (1.1) 3.5 (0.9) 3.7 (1.1) 0.15 
Tibiofemoral Cartilage Defects, 
Scores (0-8) 
    
Lateral  4.4 (1.8) 4.4 (1.7) 4.3 (1.9) 0.80 
Medial  5.2 (2.0) 4.9 (2.1) 4.7 (2.1) 0.29 
Tibiofemoral Bone Marrow Lesions, 
Scores (0-18) 
    
Lateral 0.6 (1.0) 0.9 (1.4) 0.9 (1.4) 0.48 
Medial  1.7 (2.7) 1.6 (2.6) 1.3 (2.2) 0.55 
Effusion-Synovitis Volume, cm3 5.7 (5.6) 8.0 (9.5) 8.4 (8.5) 0.14 
WOMAC Score System     
Pain (0-500) 144.2 (99.0) 130.0 (77.4) 133.8 (86.6) 0.91 




Stiffness (0-200) 66.9 (44.8) 61.5 (39.1) 59.6 (39.4) 0.64 
Function (0-1700) 524.2 (307.0) 440.7 (269.1) 461.8 (308.5) 0.37 
Nonsteroidal anti-inflammatory drugs 
use, No. (%) 
13 (28.3%) 19 (27.9%) 70 (31.0%) 0.86 
Values are mean (SD) unless otherwise stated. 
One-way ANOVA or Kruskal-Wallis rank test was used for the comparisons.  
4.3.2 Change in knee joint structures   
There was a dose-response relationship between the status of serum vitamin D and change in 
total tibial cartilage volume (Figure 4.1). Participants with consistently sufficient vitamin D 
experienced significantly less loss of total tibial cartilage volume per year than participants 
with consistently insufficient vitamin D (Table 4.2, Figure 4.1). The differences between these 
two groups and among three groups remained significant after adjustment for age, sex, body 
mass index and change in season of blood sampling. A similar pattern was seen for medial and 
lateral tibial cartilage volume but the trend did not reach statistical significance in adjusted 
analyses (all P≤ 0.10) (data not shown). Similarly, participants with consistently sufficient 
vitamin D had significantly less increases in effusion-synovitis volume (absolute and 
percentage per year) compared with participants with consistently insufficient vitamin D 
(Table 4.3, Figure 4.2). The differences between these two groups and among three groups 
remained significant after adjustment for age, sex, body mass index and season of blood 
sampling (Table 4.3). In contrast, there were no significant differences in change in cartilage 
volume or effusion-synovitis volume between the fluctuating and consistently insufficient 
vitamin D groups. Additionally, there were no significant differences in changes in total 
cartilage defects and bone marrow lesions between and among groups (Table 4.2 and Table 4.3). 
We further adjusted for use of nonsteroidal anti-inflammatory drugs and found that the results 
remained largely unchanged (data not shown).  
  




Figure 4.1 Tibial Cartilage Volume Change (%/y) in knee OA patients with or without 
sufficient serum vitamin D levels over 24 months 
 
Consistently insufficient vitamin D group: serum 25-OHD≤ 50nmol/l at both month 3 and 24; 
Fluctuating vitamin D group: serum 25-OHD> 50nmol/l at either time point;  
Consistently sufficient vitamin D group: serum 25-OHD> 50nmol/l at both month 3 and 24. 
  




Table 4.2 Associations between maintaining vitamin D sufficiency and changes in cartilage 
volume and cartilage defects over 24 months 
The dependent variables are percentage change in cartilage volume per year or absolute change 
in cartilage defects over 24 months; 
*Adjusted for age, sex and body mass index and change in season of blood sampling. 
  
 Univariable Multivariable* 






Total tibial Cartilage Volume 
Change (%/y) 
    
Consistently insufficient Reference Reference 
Fluctuating  1.7 (-0.3, 3.6) 0.10 1.5 (-0.5, 3.5) 0.15 
Consistently sufficient 2.2 (0.4, 4.0) 0.02 2.1 (0.3, 3.9) 0.03 
P for trend  0.02  0.02 
Change in Total Tibiofemoral 
Cartilage Defects 
    
Consistently insufficient Reference Reference 
Fluctuating  -0.3 (-0.8, 0.3) 0.40 -0.2 (-0.8, 0.4) 0.42 
Consistently sufficient -0.4 (-0.9, 0.1) 0.16 -0.4 (-0.9, 0.1) 0.15 
P for trend   0.16  0.15 




Figure 4.2 Effusion-Synovitis Volume Change (%/y) in knee OA patients with or without 
sufficient serum vitamin D levels over 24 months  
 
Consistently insufficient vitamin D group: serum 25-OHD≤ 50nmol/l at both month 3 and 24; 
Fluctuating vitamin D group: serum 25-OHD> 50nmol/l at either time point;  
Consistently sufficient vitamin D group: serum 25-OHD> 50nmol/l at both month 3 and 24. 
  




Table 4.3 Association between maintain vitamin D sufficiency and change bone marrow 









Change in Total Tibiofemoral bone 
marrow lesions 
    
Consistently insufficient Reference Reference 
Fluctuating  0.6 (-0.5, 1.6) 0.28 0.6 (-0.5, 1.6) 0.30 
Consistently sufficient 0.5 (-0.4, 1.4) 0.25 0.5 (-0.4, 1.4) 0.25 
P for trend  0.36  0.33 
Effusion-Synovitis absolute Volume 
Change (ml) 
    
Consistently insufficient Reference Reference 
Fluctuating  0.5 (-2.8, 3.8) 0.77 0.7 (-2.5, 3.9) 0.66 
Consistently sufficient -2.4 (-4.5, -0.2) 0.03 -2.5 (-4.7, -0.2) 0.03 
P for trend  0.01  <0.01 
Effusion-Synovitis volume Change (%/y)     
Consistently insufficient Reference Reference 
Fluctuating  -9.5 (-118.4, 99.3) 0.86 2.2 (-112.2, 116.6) 0.97 
Consistently sufficient -69.5 (-133.4, -5.6) 0.03 -61.8 (-121.9, -1.7) 0.04 
P for trend  0.01  0.01 
The dependent variables are absolute change in bone marrow lesions or percentage change per 
year/absolute change in effusion-synovitis volume over 24 months; 
* Adjusted for age, sex and body mass index and change in season of blood sampling. 




4.3.3 Changes in knee symptoms  
Changes in WOMAC scores over 24 months are shown in Table 4. There were significant 
differences in WOMAC physical function between consistently sufficient and consistently 
insufficient vitamin D groups in the mixed-effect models, adjusted for age, sex, body mass 
index and change in season of blood sampling (Table 4.4). Physical function improved time-
dependently in consistently sufficient vitamin D group while fluctuated in other two groups 
over 24 months (Figure 4.3). The differences in total WOMAC score and physical function 
were significant among three groups (Table 4.4). There were no significant differences in 
WOMAC pain and stiffness between or among groups (Table 4.4). After further adjustment 
for nonsteroidal anti-inflammatory drugs use, the results remained largely unchanged (data not 
shown). 
Table 4.4 Associations between maintaining vitamin D sufficiency and changes in clinical 
symptoms over 24 months 
 
Change Multivariable* P 
Value Mean (95%CI) β (95%CI) 
Total WOMAC Score    
Consistently insufficient -123.2 (-236.1, -10.4) Reference  
Fluctuating -111.4 (-194.8, -28.0) 11.8 (-128.5, 152.1) 0.87 
Consistently sufficient -240.4 (-298.4, -182.5) -117.2 (-244.1, 9.6) 0.07 
P for trend   <0.01 
Pain    
Consistently insufficient -34.7 (-66.6, -3.0) Reference  
Fluctuating -31.7 (-54.7, -8.8) 3.0 (-36.2, 42.3) 0.88 
Consistently sufficient -50.2 (-63.7, -36.6) -15.4 (-49.9, 19.2) 0.38 
P for trend   0.11 




Stiffness    
Consistently insufficient -11.7 (-25.1, 1.6) Reference  
Fluctuating -16.5 (-27.1, -6.0) -4.7 (-21.7, 12.3) 0.59 
Consistently sufficient -20.3 (-26.4, -14.2) -8.5 (-23.2, 6.1) 0.25 
P for trend   0.17 
Function    
Consistently insufficient -76.0 (-153.6, 1.6) Reference  
Fluctuating -61.9 (-118.5, -5.3) 14.8 (-82.6, 112.2) 0.77 
Consistently sufficient -170.8 (-212.8, -128.8) -94.2 (-183.8, -4.5) 0.04 
P for trend   <0.01 
WOMAC: Western Ontario McMaster Osteoarthritis Index; VAS: Visual Analog Scale;  
Mixed effect model adjusted for age, sex, body mass index and change in season of blood 
sampling; 
Change in WOMAC scores results are generated from mixed models adjusted for age, sex and 
body mass index and change in season of blood sampling. 
  




Figure 4.3 Changes in WOMAC Function in knee OA patients with or without sufficient 
serum vitamin D levels over 24 months 
 
Consistently insufficient vitamin D group: serum 25-OHD≤ 50nmol/l at both month 3 and 24; 
Fluctuating vitamin D group: serum 25-OHD> 50nmol/l at either time point;  
Consistently sufficient vitamin D group: serum 25-OHD> 50nmol/l at both month 3 and 24. 
4.4 Discussion  
To the best of our knowledge, this study is the first describing the differences in disease 
progression and symptoms among people with knee osteoarthritis by vitamin D status over 
time. It demonstrated that participants who maintained sufficient serum 25(OH)D levels over 
two years had decreased loss of tibial cartilage volume and less increase in effusion-synovitis 
volume comparing with those who did not. In addition, WOMAC physical function in 




participants with persistent vitamin D sufficiency improved significantly more than those with 
persistent vitamin D insufficiency. However, we did not find significant differences in changes 
in cartilage defects, bone marrow lesions or knee pain between groups. 
Results from previous randomised controlled trials have been mixed and do not provide 
consistent results146 148-150. McAlindon et al reported no effect of vitamin D supplementation 
(vitamin D3 2000 IU/day over two years, n=146) on cartilage volume loss or knee pain in 
patients with knee osteoarthritis146. However, the major limitations of this study were small 
sample size, the inclusion of participants with both vitamin D sufficiency and insufficiency, 
and the inclusion of participants with severe disease147. Participants with sufficient vitamin D 
may not benefit from vitamin D supplementation and patients with severe disease are unlikely 
to respond to any treatment147. Furthermore, a recent trial reported that vitamin D 
supplementation for three years (800IU per day for three years, n=474) did not slow 
progression of joint space narrowing (JSN) or reduce WOMAC pain, stiffness and function in 
knee osteoarthritis 148. However, the researchers used a radiographic measurement as the 
outcome, which is less sensitive for change. In contrast, another randomised controlled trial 
reported that vitamin D supplement at a high dose (60,000 IU per day for 10 days followed by 
60,000 IU once a month for a year, n=106) reduced knee pain and improved function in knee 
osteoarthritis, but this study was limited by its small sample size, short follow-up period and 
not examining structural change149.  The VIDEO study aimed to overcome some of the 
limitations of previous studies but still had consistent negative results for the primary outcomes. 
In the secondary analyses, we found that the intervention group had small but statistically 
significant improvements in VAS knee pain and WOMAC function when compared with the 
placebo group150.  In addition, 62% participants achieved a higher level of 25(OH)D (>50 
nmol/l) at month 24 in the placebo group (unpublished data), which was thought in part to 
result from changes in lifestyle (e.g., sun exposure), dietary supplementation, supplementation 
of vitamin D outside the trial and seasonal variation. 
We hypothesised that the high proportion of sufficient vitamin D level in the placebo group 
might dilute a beneficial effect of vitamin D supplementation. Thus we performed a post-hoc 
analysis to examine if maintaining sufficient vitamin D levels over time was associated with 
beneficial effects on joint structural and symptomatic changes in knee osteoarthritis patients in 




VIDEO study. Those patients who maintained sufficient serum vitamin D levels over two years 
had less loss of total tibial cartilage volume per year than those who did not. Furthermore, there 
was a dose-response relationship between the status of serum vitamin D (consistently 
insufficient, fluctuating and consistently sufficient) and change in total tibial cartilage volume. 
In contrast, changes in cartilage defects and bone marrow lesions were not significantly 
different between and among groups. These results were largely consistent with the findings 
from two high-quality cohort studies222 223. Felson et al223 reported that low 25(OH)D status 
was not associated with change in cartilage defects in knee osteoarthritis patients while we 
reported that high serum 25(OH)D levels were associated with decreased knee cartilage volume 
loss over 2.7 years in older adults222. 
The relationship between vitamin D status and joint effusion-synovitis in knee osteoarthritis 
patients is unknown. In the VIDEO study, we recently reported that vitamin D supplementation 
significantly reduced the increase in effusion-synovit volume compared with placebo in 
patients with knee osteoarthritis particularly those with baseline effusion-synovitis224. The 
results from this study were consistent with this. The current study found that persistent vitamin 
D sufficiency was associated with improvement in physical function and total WOMAC score, 
but not with WOMAC pain and WOMAC stiffness. Again, these results were largely consistent 
with the findings from the VIDEO trial 150.  
Overall, our results suggest that maintaining sufficient serum vitamin D may have a small but 
beneficial effect on retarding cartilage loss, reducing joint inflammation and improving 
physical function in knee osteoarthritis patients. The analyses in the current study have enabled 
us to use the actual serum vitamin D levels to define groups, which can reduce the potential 
confounding effect from those who achieved sufficient vitamin D levels in the placebo group 
during the trial. However, these data were post hoc and data-driven and need to be confirmed 
by further clinical trials. Further, loss of follow-up bias would exist; however, the retention rate 
in this trial was high (82%), and we used inverse probability weighting to count the impact of 
the missing values. In addition, we defined consistent vitamin D sufficiency or deficiency using 
25(OH)D levels at only month 3 and 24, but the course of 25(OH)D levels between these 
measurements were unknown. 




In conclusion, this post hoc analysis suggests beneficial effects of maintaining vitamin D 
sufficiency on cartilage loss, effusion-synovitis and physical function in people with 







Chapter 5 Vitamin D and inflammation in OA 
This manuscript has been published (Zheng et al British Journal of Nutrition 2018; 120: 41-
48). The typeset version of the manuscript as it appeared in the journal is in Appendix II. The 
text of this chapter is the same as the published version, except where changes have been 
requested by the examiners. Thus, there are some repetitions of the methods.  
  





Osteoarthritis (OA) is a common chronic joint disease, associated with increased morbidity 
and disability risk and contributing to an enormous financial burden on health care systems 
worldwide210. In recent years, the pathophysiologic concept of OA has been changed from a 
degenerative joint disorder to a more complex concept involving multiple aetiologies and 
pathogeneses225. Inflammation is intricately linked to the etiology of OA and has been 
implicated in the pathogenesis of OA226. Experimental and observational studies have 
demonstrated that inflammatory and/or metabolic biomarkers are mediators of the 
inflammatory process of OA227. In addition, there is increasing evidence for a potential role of 
vitamin D deficiency in OA. Vitamin D receptor (VDR) is expressed in chondrocytes, 
osteoclasts and osteoblasts, and vitamin D can reduce bone turnover and cartilage degradation, 
and thus has potential to delay the development and progression of OA30 121. 
Interestingly, several experimental studies have reported that vitamin D may reduce the 
inflammatory response by modulating human monocyte function or VDR signalling136 228. 
Observational studies have shown that vitamin D deficiency is associated with increased 
inflammation in chronic conditions, including asthma, inflammatory bowel disease and 
rheumatoid arthritis135 229. Such evidence suggests that increased inflammation may be a key 
underlying mechanism linking vitamin D deficiency to OA, and vitamin D could modify OA 
disease progression through inhibition of inflammation. Previous studies have examined the 
effect of vitamin D supplementation on inflammatory biomarkers in older adults and patients 
with some chronic diseases, and have shown inconsistent results230-233, but there has no study 
being reported whether vitamin D supplementation has effects on inflammatory and metabolic 
biomarkers in OA patients.  
Recently we reported that compared with placebo, vitamin D supplementation had no 
significant effects on MRI-measured tibial cartilage volume or the Western Ontario and 
McMaster Universities Arthritis Index (WOMAC) assessed knee pain150, but significantly 
reduced MRI-measured joint effusion-synovitis in patients with symptomatic knee OA151. This 
suggests that vitamin D supplementation could have anti-inflammatory effects by regulating 
serum levels of inflammatory or metabolic biomarkers in knee OA patients. The aim of the 
current study was, therefore, to determine whether vitamin D supplementation affected serum 




inflammatory and metabolic biomarkers and whether variation in vitamin D status over two 
years was associated with change in biomarkers in patients with knee OA and vitamin D 
deficiency.  
5.2 Materials and Methods  
5.2.1 Study design 
This study was a post-hoc analysis of the Vitamin D Effect on Osteoarthritis (VIDEO) study, 
which was a multicenter randomized, double-blind, placebo-controlled trial in knee OA 
patients with vitamin D deficiency. The method and protocol of the trial were described 
previously175. The trial was conducted from June 2010 to December 2013.  
5.2.2 Participants  
Briefly, eligible participants who had knee symptomatic OA (assessed using American College 
of Rheumatology, ACR criteria)18 at least for 6 months and had pain of >20 mm on a 100-mm 
visual analog scale (VAS) with low levels of 25-hydroxyvitamin D [25(OH) D, between 12.5 
and 60 nmol/L] were enrolled in Tasmania and Victoria, Australia. Participants with the 
following conditions were excluded: severe radiographic changes (grade 3 of Altman and Gold 
Atlas), severe knee pain on standing (> 80 mm on a 100-mm VAS), contraindications to 
magnetic resonance imaging (MRI), rheumatoid arthritis (RA) or psoriatic arthritis, lupus, 
cancer, severe cardiac or renal impairment, hypersensitivity to vitamin D, conditions affecting 
oral drug absorption, anticipated knee or hip surgery within the next 2 years, history of 
significant trauma of knees (e.g. arthroscopy or injury to ligaments or menisci within one year 
preceding the study) and history of taking vitamin D or other investigational drugs, like some 
compound drugs including vitamin D affected serum vitamin D levels, within the last 30 
days175. 
After the trial had completed, 200 participants were randomly selected for the measurements 
of inflammatory and metabolic biomarkers from Tasmania. 
5.2.3 Ethics 




Ethics approvals was received from Tasmania Health and Human Medical Research Ethics 
Committee (reference number H1040) and Monash University Human Research Ethics 
Committee (reference number CF10/1182-2010000616). 
5.2.4 Randomization and treatment 
Participants were allocated to either vitamin D or placebo arm at a ratio of 1:1 based on 
computer-generated random numbers. Allocation concealment was ensured by a centrally 
automated allocation procedure with security in place to ensure allocation data cannot be 
accessed or influenced by any person from the investigative team. Participants received oral 
vitamin D capsules at a dose of 50,000 IU vitamin D3 (cholecalciferol) per month for 24 months 
in the treatment group. Participants received an identical inert placebo capsule in the placebo 
group175.   
5.2.5 Serum inflammatory and metabolic biomarkers levels measurement  
All fasting blood samples were collected at baseline and month 24. The measurements were 
performed according to the manufacturer’s instruction. Serum levels of high-sensitive C-
reactive protein (hs-CRP), IL-6, IL-8, IL-10, resistin, leptin, adiponectin, adipsin and apelin-
36 were measured. Serum hs-CRP was measured by enzyme immunoassays (IBL Inc.). Serum 
leptin and apelin-36 were measured by enzyme-linked immunosorbent assay (ELISA, Phoenix 
Pharmaceuticals Inc.). Serum adiponectin, adipsin, resistin were measured by ELISA 
(Millipore Inc.). Serum IL-6, IL-8, and IL-10 were measured by Bio-plex Luminex assay kits 
(Bio-Rad Laboratories Inc.). The inter-assay and intra-assay CVs were <10% and < 15% for 
all inflammatory biomarkers.  
5.2.6 Serum vitamin D level measurement  
Serum 25(OH)D was measured at baseline, month 3 and 24 using direct competitive 
chemiluminescent immunoassays (DiaSorin Inc.). The intra-assay and inter-assay coefficients 
of variation were 3.2% and 6.0%, respectively150. In addition, the season of blood sample was 
recorded. In this study, we defined serum 25(OH)D below than 50nmol/l as vitamin D 
deficiency.  




5.2.7 Variation in vitamin D status  
Participants were classified into two groups according to the levels of 25(OH)D at month 3 and 
24 as follows: not consistently sufficient (serum 25(OH)D≤50nmol/l at either month 3 or 24), 
and consistently sufficient (serum 25(OH)D>50nmol/l at both month 3 and 24). 
5.2.8 Assessment of effusion-synovitis and cartilage volume  
MRI scans of the study knee were obtained according to a standardized protocol using a 1.5 T 
whole-body MRI unit with a commercial transmit-receive extremity coil at baseline and two 
years.  
Effusion-synovitis assessed using T2-weighted/proton density–weighted fast spin echo (FSE) 
sequences at four regions (suprapatellar pouch, central portion, posterior femoral recess and 
subpoploteal recess). Effusion-synovitis in each subregion was scored individually according 
to Whole-Organ Magnetic Resonance Imaging Score (WORMS), grading collectively from 0 
to 3 in terms of the estimated maximal distention of the synovial cavity: 0 refers to normal; 1 
to <33% of maximum potential distention; 2 to 33%–66% of maximum potential distention; 3 
to >66% of maximum potential distention. The presence of effusion-synovitis of the whole 
joint was defined as a score of ≥2 in any subregion151.  
Effusion-synovitis volume at 4 regions were isolated from the total volume selecting each 
region of interest (ROI) according to the intra-articular fluid-equivalent signal on a section-by-
section basis and then resampled by means of bilinear and cubic interpolation for final 3D 
rendering using OsiriX imaging software (32-bit version 5.9, Pixmeo SARL)234. The intra-class 
correlation coefficient were from 0.96 to 0.97235. 
Cartilage volume was determined using the previously described image processing 
techniques175. The volumes of individual cartilage plates (medial tibial and lateral tibial) were 
isolated by manually drawing disarticulation contours around the cartilage boundaries on a 
section-by-section basis then resampled using bilinear and cubic interpolation for final three-
dimensional rendering using OsiriX imaging software. The coefficient of variation was 2.1% 
to 2.2%235. Total tibial cartilage volume was calculated as the sum of the medial tibia and 




lateral tibial cartilage plates. Change in cartilage volume and effusion-synovitis volume were 
calculated as follows:  
Absolute	change	(ml) = 345546	78	9457:; − =>?;5@A;	9457:;	 
5.2.9 Anthropometrics   
Height was measured to the nearest 0.1 cm (with shoes removed) using a stadiometer (Leicester 
Height Measure, Invicta Plastics Ltd, Leicester, UK). Weight was measured to the nearest 0.1 
kg (with shoes and bulky clothing removed) using electronic scales (Heine S-7307, Heine, New 
Hampshire, USA). Body mass index (BMI, in kg/m2) was calculated. 
5.2.10 Data analyses 
Very few studies have examined the effect of vitamin D supplementation on inflammatory 
biomarkers; therefore, there was limited information to inform our sample size calculation. 
Based on a systematic review, the absolute difference in serum hs-CRP between people with 
OA and healthy controls is estimated as 1.19mg/L236. Data from the Tasmanian Older Adult 
Cohort Study provided a standard deviation (SD) estimate of 2.78mg/L. With these estimates, 
a sample size of 87 in each group would give 80% power with a 5% probability of type 1 error 
(α= 0.05, β= 0.8)179 237 to detect this effect size for hs-CRP.  
Baseline characteristic differences between the vitamin D supplementation and placebo groups 
were compared using Student’s t-tests or Chi-square tests as appropriate. Box-cox 
transformation was used, when variables were not normally distributed, and transformed 
variables were used in the following analyses. The differences in changes of inflammatory 
biomarkers between treatment and placebo groups were analyzed using linear mixed effects 
model with adjustment for age, sex, BMI and seasonal change of blood sampling. The within-
subject correlation between the repeated measures, including baseline and follow-up data, was 
taken into account using the individual participant identification as a random effect. The effect 
of vitamin D supplementation on biomarkers was evaluated by the interaction between 
treatment and time (i.e., month). The differences in changes of inflammatory biomarkers 
between not consistently sufficient and consistently sufficient groups were analyzed using 
linear mixed effects model with adjustment for age, sex, BMI and seasonal change of blood 




sampling. Subgroup analyses were performed in participants with or without effusion-synovitis 
at baseline. We also have taken the weight change as confounder into analyses to make sure 
that the weight change did not play a role in this study. Further adjustment for changes in 
cartilage volume and effusion-synovitis volume were performed to account the effect of disease 
progression on serum biomarkers change. We used Stata 12.0 for Windows (Stata Corp LP) 
for all analyses. A p-value < 0.05 (two-tailed) was regarded as statistically significant.  
5.3 Results    
5.3.1 Baseline characteristics of participants 
A total of 599 participants were screened for eligibility, 413 participants were enrolled and 
randomly assigned to vitamin D or placebo group (261 participants in Hobart and 152 
participants in Melbourne), and 340 participants (82.0% retention rate in Hobart and 83.6% 
retention rate in Melbourne) completed the study (Figure 5.1). A total of 200 participants from 
Hobart was randomly selected for the inflammatory biomarkers’ measurements, 94 participants 
from the placebo group and 106 from vitamin D treatment group.  
The mean age of participants was 63.1 years, 107 (53.5%) were women and mean BMI was 
29.5 kg/m2. There were no significant differences in baseline characteristics (age, sex, BMI, 
serum 25(OH)D level, serum inflammatory biomarkers levels and season of blood sample) 
between the placebo and vitamin D groups (Table 5.1). There were no significant differences 
in baseline characteristics between those included and not included in this study (data not 
shown). Significant differences in baseline characteristics, inflammatory and metabolic 
biomarkers between consistently sufficient and not consistently sufficient groups were not 
found (data not shown).




Figure 5.1 Flowchart of the study 




Table 5.1 Baseline characteristics of participants 
 





Age, years 63.3 (7.5) 62.8 (7.3) 0.60 
Women, No. (%) 53 (50.0%) 54 (57.4%) 0.29 
BMI, kg/m2 29.4 (7.5) 29.6 (4.0) 0.80 
Serum 25(OH)D (nmol/L) 42.5 (11.7) 43.5 (12.6) 0.57 
Serum biomarker    
*hs-CRP (ug/ml) 1.5 (0.8, 2 2.6) 1.3 (0.7, 2.5) 0.62 
*IL-6 (pg/ml) 1.4 (0.4, 3.8) 1.2 (0.4, 3.7) 0.81 
*IL-8 (pg/ml) 7.8 (5.7, 10.4) 7.6 (6.1, 10.9) 0.98 
*IL-10 (pg/ml) 0.9 (0.3, 5.2) 0.6 (0.3, 3.5) 0.56 
Resistin (pg/ml) 38.4 (14.9) 39.3 (13.2) 0.32 
*Leptin (ng/ml) 19.2 (9.4, 58.1) 23.6 (9.7, 44.1) 0.90 
*Adiponectin (ng/ml) 32.9 (18.2, 50.3) 26.5 (15.5, 43.8) 0.11 
Adipsin (ng/ml) 4.0 (1.5) 3.9 (1.2) 0.84 
Apelin (ng/ml) 1.0 (0.3)  1.0 (0.4)  0.84 
Values are mean (standard deviation) or percentage unless otherwise stated.  
* Skewed distribution, values are median (interquartile range). 
 BMI was calculated as weight in kilograms divided by height in meters squared. Student’s t-
tests or Chi-square tests. 
Abbreviations: BMI, body mass index; hs-CRP, high sensitivity C-reactive protein; IL-6, 
interleukin-6; IL-8, interleukin-8; IL-10, interleukin-10. 




5.3.2 Vitamin D supplementation and inflammatory and metabolic biomarkers 
The mean serum 25(OH)D level increased significantly in the vitamin D treatment group (44.9 
nmol/L) compared to the placebo group (7.0 nmol/L) over two years. The effect of vitamin D 
treatment on cytokines and adipokines is shown in Table 5.2. Vitamin D supplementation had 
no significant effect on change in serum inflammatory and metabolic biomarkers. There were 
no statistically significant differences in changes in any biomarkers between the placebo and 
vitamin D groups. After further adjustment for potential confounders including the seasonal 
change of blood sample, the differences between groups remained non-significant in the mixed 
effect model (Table 5.2). Within the group, serum resistin increased by 1.9 pg/ml (95% CI: 0.1, 
3.8) in the placebo group and by 4.4 pg/ml (95% CI: 2.7, 6.2) in the vitamin D group from 
baseline to month 24. Difference in change in serum resistin between two groups was of 
borderline statistically significance (P= 0.05).  Serum adipsin increased by 0.2 ng/ml (95% CI: 
0.1, 0.4) in the vitamin D group, but did not increase in the placebo group from baseline to 
month 24. Serum hs-CRP, IL-6, IL-8, IL-10, leptin, adiponectin and apelin did not change 
significantly over 24 months in either group.  
Further analyses were performed in participants who had baseline effusion-synovitis or not. 
Results remained largely unchanged (data not shown). The results remained unchanged after 
further adjustment for change in weight, and changes in cartilage volume and effusion-
synovitis volume (data not shown).   




Table 5.2 Comparisons of change in inflammatory biomarkers between vitamin D and placebo groups over 24 months 
 Vitamin D group Change (N= 106), 
Mean (95% CI)a 
Placebo group Change (N= 94), 
Mean (95% CI)a 
Between-Group Difference, 
Mean (95% CI)b 
P 
Value 
Serum 25(OH)D (nmol/L) 45.0 (40.8, 49.0)  7.4 (3.0, 11.8) 37.5 (31.5, 43.6) 0.00 
hs-CRP (ug/ml) 0.3 (-0.2, 0.7) -0.0 (-0.5, 0.5) 0.3 (-0.4, 1.0) 0.43 
IL-6 (pg/ml) -2.3 (-5.6, 0.9) -0.7 (-4.2, 2.8) -1.6 (-6.4, 3.2) 0.51 
IL-8 (pg/ml) -3.1 (-6.5, 0.3) -0.0 (-3.7, 3.6) -3.1 (-8.1, 2.0) 0.24 
IL-10 (pg/ml) -2.0 (-9.3, 5.3) -0.7 (-8.5, 7.1) -1.3 (-12.0, 9.4) 0.81 
Resistin (pg/ml) 4.4 (2.7, 6.2) 1.9 (0.1, 3.8) 2.5 (-0.0, 5.1) 0.05 
Leptin (ng/ml) -0.2 (-3.4, 3.0) -0.8 (-4.2, 2.6) 0.6 (-4.0, 5.3) 0.79 
Adiponectin (ng/ml) ¶ 0.01 (-0.02, 0.04) 0.00 (-0.03, 0.03) 0.01 (-0.04, 0.06) 0.66 
Adipsin (ng/ml) 0.2 (0.1, 0.4) 0.1 (-0.0, 0.3) 0.1 (-0.1, 0.3) 0.39 
Apelin (ng/ml) -0.1 (-0.1, 0.0) 0.0 (-0.1, 0.1) -0.1 (-0.2, 0.0) 0.13 
¶ box-cox transformation; a Change in inflammatory biomarkers are generated from mixed models adjusted for age, sex, BMI and change in season 
of blood sampling; b Between-group difference was calculated using vitamin D group values minus placebo group values. Vitamin D status and 
change in biomarkers  




5.3.3 Vitamin status and change in biomarkers 
There were no statistically significant differences in changes of these biomarkers between 
consistently sufficient and not consistently sufficient groups (Table 5.3). In the consistently 
vitamin D sufficient group, there were significant increases in serum resistin and adipsin (3.8 
pg/ml and 0.3 ng/ml, respectively) and a significant decrease in serum IL-8 (3.0 pg/ml) from 
baseline to month 24 (Table 5.3). In contrast, there was no significant change over the study 
period in the not consistently sufficient group. Serum IL-6, IL-10, CRP, leptin, adiponectin, 
and apelin did not change significantly from baseline to months 24 in either group.  
The results remained largely unchanged if patients with and without baseline effusion-synovitis 
were separated for analyses (data not shown). Results remained largely unchanged after further 
adjustment for changes in weight, cartilage volume and effusion-synovitis volume (data not 
shown). In addition, no significant associations were found between the changes in 
inflammatory/metabolic biomarkers and change in 25(OH)D over 24 months, and the results 
remained largely unchanged after further adjustment for the baseline serum 25(OH)D level 
(except for change in resistin, P= 0.04) (data not shown).  
  




Table 5.3 Comparison of change in inflammatory biomarkers between different vitamin D status over 24 months 
 Consistently sufficient Change (N= 139), 
Mean (95% CI)a 
Not consistently sufficient Change (N= 61), 
Mean (95% CI)a 
Between-group Difference, 
Mean (95% CI)b 
P 
value 
Serum 25(OH)D (nmol/L) 37.8 (34.1, 41.6) 3.1 (-2.6, 8.7) 34.8 (28.0, 41.6) 0.00 
hs-CRP (ug/ml) 0.2 (-0.2, 0.7) -0.1 (-0.7, 0.6) 0.3 (-0.5, 1.1) 0.46 
IL-6 (pg/ml) -2.8 (-5.7, 0.0) 1.3 (-3.0, 5.6) -4.1 (-9.3, 1.0) 0.12 
IL-8 (pg/ml) -3.0 (-6.0,-0.0) 1.4 (-3.1, 6.0) -4.5 (-9.9, 1.0) 0.11 
IL-10 (pg/ml) -3.3 (-9.6, 3.1) 2.9 (-6.8, 12.6) -6.2 (17.8, 5.4) 0.29 
Resistin (pg/ml) 3.8 (2.3, 5.4) 1.9 (-0.4, 4.3) 1.9 (-0.9, 4.7) 0.18 
Leptin (ng/ml) -0.1 (-2.9, 2.7) -1.3 (-5.5, 2.9) 1.1 (-3.9, 6.2) 0.66 
Adiponectin (ng/ml) ¶ 0.02 (-0.01, 0.04) -0.01 (-0.06, 0.03) 0.03 (-0.02, 0.08) 0.26 
Adipsin (ng/ml) 0.3 (0.1, 0.4) 0.1 (-0.1, 0.3) 0.2 (-0.1, 0.4) 0.13 
Apelin (ng/ml) -0.0 (-0.1, 0.0) -0.1 (-0.1, 0.0) 0.0 (-0.1, 0.1) 0.72 




¶ box-cox transformation; a Change in inflammatory biomarkers are generated from mixed 
models adjusted for vitamin D treatment, age, sex, BMI and change in season of blood 
sampling; b Between-group difference was calculated using consistently sufficient group values 
minus not consistently sufficient group values. 
5.4 Discussion  
To the best of our knowledge, this study is the first to explore the effect of vitamin D 
supplementation on inflammatory and metabolic biomarkers in patients with knee OA and to 
compare the effect of vitamin D sufficiency on levels of serum inflammatory and metabolic 
biomarkers in OA patients. Vitamin D supplementation had no significant effects on serum 
inflammatory and metabolic biomarkers in patients with knee OA. Furthermore, there were no 
significant differences in serum inflammatory and metabolic biomarkers between those who 
were consistently sufficient and those who were not over 24 months. These results suggest that 
vitamin D supplementation and maintaining sufficient vitamin D status may not have effects 
on systemic inflammation in knee OA patients.  
Low-grade systemic inflammation triggered by abnormally inflammatory or metabolic 
biomarkers has been implicated in the OA pathogenesis. There is a vast amount of evidence 
linking inflammatory biomarkers and OA, as well as the association between vitamin D and 
inflammation. Serum hs-CRP levels were statistically significantly higher in OA group than 
control group and were associated with increased pain and decreased physical function236. 
Serum IL-6 was correlated with radiographic OA, knee cartilage loss and increased knee pain 
over time238 239. Adipokines such as leptin and resistin may disrupt cartilage homoeostasis 
through directly inducing joint structural degradation or regulating local inflammatory 
processes and are regarded as metabolic biomarkers in the inflammatory process of OA240 241. 
Serum leptin was associated with reduced knee cartilage volume and increased loss of cartilage 
thickness242. Furthermore, high serum leptin and IL-6 were associated with reduced 25(OH)D 
levels over time243. These suggest that systemic inflammation triggered by inflammatory or 
metabolic biomarkers may be a key underlying mechanism linking vitamin D deficiency to OA.  
Although there has been no previous RCT examining the effect of vitamin D supplementation 
on inflammatory and metabolic biomarkers in knee OA patients, some RCTs have examined 




the effect in healthy individuals, older adults, or patients with other chronic diseases such as 
obesity, asthma, diabetes and chronic kidney disease, and reported inconsistent results244. The 
inconsistency between these study findings may be caused by small sample sizes, diverse 
characteristics of participants, treatment with different doses, and measurements of different 
inflammatory and metabolic biomarkers for the different clinical trials245. For example, two 
RCTs with small sample size were conducted in patients with diabetes. One study reported that 
supplementation with 50,000IU vitamin D per two weeks for 12 weeks in 60 patients 
significantly reduced serum hs-CRP level compared to  the placbo group246, but another study 
reported that treatment with 50,000IU per week vitamin D and/or 1000mg calcium per day 
twice for 8 weeks did not result in significant difference in change in serum CRP and leptin, 
but did result in significant reduction in serum IL-6 and TNF-α comparing with the placebo 
group in 118 diabetic patients231. 
Our results are consistent with finding from RCTs in healthy or older adults without specific 
health conditions as vitamin D supplementation in these groups has shown no effect on 
inflammatory and metabolic biomarkers247-250. A randomised placebo-controlled trial was 
conducted in  elderly adults without a specific disease in Australia, aiming to examine the 
effects of vitamin D supplementation for 12 months on hs-CRP, leptin, adiponectin, IL-6 and 
IL-10251. IL-6 was numerically higher in those participants supplementing with 1500 µg/month 
vitamin D comparing with 750 µg/month, although this was not significant. In our current study, 
we found that vitamin D supplementation had no significant effect on serum inflammatory and 
metabolic biomarkers, with the exception of a possible effect on serum resistin, in patients with 
knee OA. Serum resistin increased twofold more in the vitamin D group than in the placebo 
group, but the difference was of borderline significance. Although evidence shows that serum 
resistin is a pro-inflammatory cytokine and is positively associated with severity of OA252, the 
clinical relevance of this finding is unknown. Subgroup analyses were performed in 
participants who had baseline effusion-synovitis or not and results remained unchanged. We 
previously reported that vitamin D supplementation relieved the progression of effusion-
synovitis in patients with an inflammatory OA phenotype151. These indicated that vitamin D 
supplementation would have effects on local rather than systemic inflammation. The 
underlying mechanisms are unclear and need to be explored by further studies.  




A high proportion of participants in the placebo group achieved sufficient vitamin D level in 
month 24 (62% participants >50nmol/L) in VIDEO study, which may have masked the effect 
of vitamin D supplementation on inflammatory and metabolic biomarkers. Therefore, we 
performed further post-hoc analyses to examine if maintaining sufficient vitamin D level over 
the treatment period had effects on the biomarkers. Although serum resistin and adipsin 
increased, and serum IL-8 decreased from baseline to months 24 in the consistently vitamin D 
sufficient group, changes in serum resistin, adipsin and IL-8 were not significantly different 
between the patients with different vitamin D status. Up to now, only one cross-sectional study 
compared the level of inflammatory cytokines (IL-1β, 2, 4, 5, 6, 8,10, 12,13 and hs-CRP) in 
different  serum vitamin D status (deficient, insufficient or sufficient) in patients with knee OA, 
and did not find that vitamin D status was associated with circulating inflammatory 
biomarkers253. These results were generally consistent with the findings in our current study. 
Maintaining serum vitamin D sufficiency may not have effects on systemic inflammation in 
knee OA patients. 
We used the direct competitive chemiluminescent immunoassays (Diasorin Liaison assay) to 
measure the serum 25(OH)D which may be not as sensitive and specific high performance 
liquid chromatography (HPLC) methodology; however, it showed good correlation with HPLC, 
and would also be specific for both 25(OH)D2 and 25(OH)D3254 255. The vitamin D status, 
measured via serum 25(OH)D concentrations, can be affected by factors such as obesity. In 
addition, expression of vitamin D dependent genes could be served as a marker of vitamin D 
status, and this may also influence the effect of vitamin D supplementation on inflammatory 
markers256 257. These need to be explored in future studies. 
There were some limitations of the current study. First, it was a post-hoc analysis within a 
subsample of an RCT, which was not designed to examine the effect of vitamin D 
supplementation on inflammatory and metabolic biomarkers in patients with knee OA. The 
findings need to be confirmed by further RCTs using these biomarkers as the primary endpoints. 
Second, this study had reduced sample size than what was designed for the original study. 
However, the sample size is sufficient to detect a significant difference for hs-CRP. Third, there 
was a high proportion of participants in the placebo group who achieved sufficient vitamin D 
levels at month 3 and month 24 (62% participants >50nmol/L) in the RCT study, which could 




have diluted the effect of vitamin D supplementation. Thus, we performed further post-hoc 
analyses using variations in vitamin D status over the treatment period and the results were 
consistent. Fourth, 3 time points (baseline, 3 months to 24 months) may not be adequate to 
define the “consistently or inconsistently vitamin D sufficient”, and the inflammatory and 
metabolic markers were not measured at an intermediate time point. It was unknown if vitamin 
D supplementation had intermediate effects on inflammatory markers in knee OA patients. 
Therefore, further studies are required.  
In conclusion, vitamin D supplementation and maintaining vitamin D sufficiency did not alter 
serum levels of inflammatory and metabolic biomarkers over 2 years in knee OA patients who 







Chapter 6 Effects of vitamin D on depressive symptoms 
This manuscript has been published (Zheng et al, Journal of the American Medical Directors 
Association 2018). The typeset version of the manuscript as it appeared in the journal is in 
Appendix II. The text of this chapter is the same as the published version, except where changes 
have been requested by the examiners. Thus, there are some repetitions of the methods. 




6.1 Introduction  
Depression is a major global public-health problem and is projected to be the second leading 
cause of disease burden by the year 2030258. Due to population ageing, depression in later life 
is a common comorbidity of many chronic diseases85. Although depression is less prevalent 
among older than younger adults, it still has detrimental consequences259. Similarly, 
osteoarthritis (OA) is the most prevalent chronic joint disease and the leading cause of 
disability in individuals and has a substantial financial burden on the health system6 24. It is 
predicted that 130 million individuals of more than 60 years old will suffer from OA worldwide 
by 2050260. Depression and depressive symptoms are common among individuals with OA. 
Stubbs and colleagues reported that 19.9% of those with OA had depressive symptoms, with a 
relative risk of 1.17 in those with OA compared to those without86. Concomitant depression in 
OA patients contributes to its increased disease burden and troubles with disease 
management261 262. 
Vitamin D deficiency or insufficiency is a global public health problem and affects nearly a 
billion people worldwide113. Vitamin D deficiency is associated with a range of mental 
disorders including depression113. Vitamin D receptors (VDR) exist in the brain, and vitamin 
D can boost the levels of brain chemical monoamines, which is necessary for a positive mood 
and has possible neuroprotective roles that vitamin D may play through its effects on 
inflammation153 263-265. Furthermore, a positive association between vitamin D deficiency and 
depression has been reported in previous epidemiological and clinical studies in the general 
population including children, older adults and patients with other chronic diseases159 266 267; 
however, it remains unknown whether the relationship is causal266. Although the biological 
mechanisms underlying the associations between vitamin D deficiency and depression are 
unclear and may be complicated, the therapeutic potential of vitamin D supplementation for 
depression has been highlighted159. Thus far, randomized controlled trial (RCT) evidence 
examining whether vitamin D supplementation can improve depression has been investigated 
in the general population and shows inconsistent findings. The contradictory evidence may be 
caused by variations in baseline vitamin D levels, vitamin D dosages, sample sizes, duration 
of follow-up, outcome measurements and investigated populations162. A meta-analysis 
reviewed nine clinical trials and reported no significant reduction in depression after vitamin 




D supplementation, but most of the studies focused on individuals with low levels of depression 
or who had sufficient vitamin D at baseline164. Further well-designed vitamin D 
supplementation RCTs among individuals who are both depressed and vitamin D deficient are 
needed.  
Although depression is prevalent in OA patients and a positive association between vitamin D 
deficiency and depression has been demonstrated, no study has examined the effect of vitamin 
D supplementation on depressive symptoms in people with OA so far. This study primarily 
aims to determine the effect of vitamin D supplementation on depressive symptoms in patients 
with knee OA and vitamin D deficiency. An ancillary aim of this study is to determine whether 
maintaining sufficient serum vitamin D has beneficial effects on depressive symptoms150. 
6.2 Materials and Methods 
6.2.1 Trial design and participants 
This study is a pre-specified secondary analysis of the Vitamin D Effect on Osteoarthritis 
(VIDEO) study, which was conducted from June 2010 to December 2013. VIDEO was a 
multicenter, randomized, double-blind, placebo-controlled trial to determine the effect of 
vitamin D supplementation on knee structures and symptoms among patients with symptomatic 
knee OA. This secondary analysis aims to determine the effect of vitamin D supplementation 
on depressive symptoms in patients with knee OA and vitamin D deficiency. The ancillary aim 
of determining whether maintaining sufficient serum vitamin D has beneficial effects on 
depressive symptoms was added because there was a high proportion of participants having 
unforeseen improvements in serum 25-hydroxyvitamin D [25(OH)D] levels in the placebo 
group of our RCT as previously published235.  
The methods were described in the published protocol of the trial 175, and the results for primary 
outcomes have been published150. Participants who suffered from symptomatic knee OA, 
which was assessed using the American College of Rheumatology (ACR) criteria18, for at least 
6 months with knee pain >20 mm on a 100-mm visual analog scale (VAS) and serum levels of 
25-hydroxyvitamin D [25(OH)D] between 12.5 and 60 nmol/L were enrolled in Tasmania and 
Victoria, Australia. Participants with grade 3 radiographic changes (Altman and Gold Atlas), 
severe knee pain on standing (>80 mm on a 100-mm VAS), other rheumatic diseases such as 




rheumatoid arthritis, psoriatic arthritis and lupus, contraindication to MRI, cancer, severe 
cardiac or renal impairment, hypersensitivity to vitamin D, anticipated knee or hip surgery 
within the next 2 years and history of taking vitamin D within the previous 1 month were 
excluded175.  
6.2.2 Ethics  
All participants provided informed written consent and the study was approved by the Ethics 
Committee in Tasmania and Melbourne (reference number: H1040 and CF10/1182-
2010000616, respectively).  
6.2.3 Randomization and intervention  
Participants were allocated to either the vitamin D or placebo arm at a ratio of 1:1 based on 
computer-generated random numbers. Allocation concealment was ensured by a centrally 
automated allocation procedure with security in place to ensure allocation data could not be 
accessed or influenced by any person from the investigative team. Participants, research 
coordinators and investigators were all blinded to treatment assignment. Blinding was 
maintained until all data were collected, cleaned, confirmed for accuracy and analyses of 
primary outcomes were performed. 
Participants received 50,000IU (1.25mg) oral vitamin D3 capsule (cholecalciferol) monthly for 
24 months or an identical inert placebo175. Both the vitamin D3 compound and placebo were 
prepared by and purchased from Nationwide Compounding Pharmacy, Melbourne, Australia. 
6.2.4 Patient health questionnaire-9 
Depressive symptoms were assessed using the patient health questionnaire (PHQ-9) at baseline, 
month 3, 6, 12 and 24. PHQ-9 is a valid and reliable self-reported depression instrument, which 
is widely used in multipurpose diagnoses, severity measures in the clinic, as well as assessing 
depression outcomes in research204 205. It is a nine-item questionnaire with a score range of 0 
to 27, with each item being scored from 0  to 3 (not at all, several days, more than half days 
and nearly every day). Using the mental health professional interview as the criterion standard, 
PHQ-9 scores of 5-9, 10-14, 15- 20 and >20 represent mild, moderate, moderately severe and 




severe depression, respectively. A PHQ-9 scores ≥ 10 has a sensitivity of 88% and specificity 
of 88% for major depression204.   
6.2.5 Serum 25(OH)Dmeasurement  
Serum 25(OH)D was measured at baseline, month 3 and 24 using direct competitive 
chemiluminescent immunoassays, which is an accurate and reproducible automated tool182 
(DiaSorin Inc.). The Intra-assay and inter-assay coefficients of variation were 3.2% and 6.0%, 
respectively150. The season of blood sample was recorded. 
6.2.6 Knee symptoms measurement  
Knee symptoms were assessed at baseline and months 3, 6, 12, and 24 using the Western 
Ontario and McMaster Universities OA Index (WOMAC), which is a widely used instrument 
to evaluate the functional capacity in patients with OA and demonstrates high performance in 
clinical trials183. The Index contains 24 questions (5 related to pain, 2 to stiffness and 17 to 
physical function) with scores ranging from 0 (none) to 100 (severe) for each question. The 
total WOMAC score (0-2400) is the sum of subscale scores including pain (0-500), stiffness 
(0-200) and physical function (0-1700).  
6.2.7 Physical activity  
Physical activity (PA) was assessed by the international physical activity questionnaire (IPAQ), 
which has been developed and tested for use in adults (age range of 16-69 years). PA status 
(insufficiently active, sufficiently active and highly active) was calculated according to the 
scoring protocol available at http://www.ipaq.ik.se. The IPAQ instrument was valid and 
reliable for self-reports and monitoring population levels of physical activity among adults (18 
to 65 years old) in diverse settings268.  
6.2.8 Anthropometrics and social demographic characteristics data  
Height was measured to the nearest 0.1 cm (with shoes removed) using a stadiometer (Leicester 
Height Measure, Invicta Plastics Ltd, Leicester, UK). Weight was measured to the nearest 0.1 
kg (with shoes and bulky clothing removed) using electronic scales (Heine S-7307, Heine, New 




Hampshire, USA). Body mass index (BMI, in kg/m2) was calculated175. Obesity status were 
defined as the normal weight, overweight and obese depending the BMI according the 
criteria269. Patients filled out a questionnaire which collected information on education history 
(grade 0: less than high school, grade 1: high school degree and grade 2: superior than high 
school degree), current regular smoker (yes or no), current medical conditions and medication 
uses. 
6.2.9 Statistical methods  
The primary analysis compared the effect of vitamin D supplementation on depressive 
symptoms as measured by the PHQ-9 between the vitamin D group and the placebo group.  
Given the previously published high level of correction of deficiency in the placebo group (62% 
reached vitamin D sufficiency at month 24 in the placebo group), a secondary analysis was 
also performed by vitamin D status150 270. Participants were classified into two groups 
according to their serum 25(OH)D levels at month 3 and 24 as follows: not consistently 
sufficient (serum 25(OH)D≤50nmol/l at month 3 and/or 24), and consistently sufficient (serum 
25(OH)D>50nmol/l at both month 3 and 24).  
Based on Lowe’s study205, we anticipated a standard deviation (SD) of 5.4 for the change in 
PHQ-9. The sample size calculation assumed α = 0.05 and β = 0.20 and was performed based 
on the Cohen formula179. With 400 participants, a difference between groups of 1.2 units on 
the score is detectable with 80% power.  
Differences in baseline characteristics between vitamin D and placebo groups were compared 
using independent t-tests or Chi-square tests as appropriate. Repeated-measures mixed effect 
models were used to examine changes in PHQ-9 scores over 24 months in the vitamin D 
supplementation versus the placebo group and the group that maintained vitamin D sufficiency 
between month 3 and 24 versus the group that did not maintain vitamin D sufficiency. The 
models were adjusted for age, sex and BMI. Further adjustments for knee pain, joint function, 
baseline PHQ-9 score, serum 25(OH)D level, self-reported depression and/or anti-depressant 
medication were performed. Missing data due to loss to follow-up or nonresponses were 
accounted for in the multilevel mixed-effect model. Sub-group analysis was performed to 
examine whether the effect of vitamin D supplementation and maintaining vitamin D 




sufficiency varied by the presence of depressive symptoms at baseline. A reduction of PHQ-9 
score of greater than 2.59/27 was used as the cut-off for the minimal clinically important 
difference (MCID) based on the Lowe’s recomendation which was developed for those with 
major depression205. 
All tests were two-sided and a P value <0.05 was considered as statistically significant. Stata 
version 12.0 was used to perform statistical analyses. 
6.3 Results  
6.3.1 Baseline characteristics of participants  
Figure 6.1 shows the flow of study participants. Five hundred and ninety nine participants were 
screened for eligibility, and 413 participants were enrolled (Figure 6.1). 209 and 204 
participants were randomly assigned to receive vitamin D and placebo, respectively. Over 24 
months, 340 participants (intervention N= 181, placebo N= 159, 82.3% retention rate) 
completed the study. The mean age of participants was 63.2 (7.0) years, 208 (50.3%) were 
women and mean BMI was 29.6 (5.0) kg/m2. The baseline prevalence of depression (PHQ-9 
score ≥5) was 25.4% (mild and moderate to severe depression was 17.6% and 7.8%, 
respectively). The actual range of PHQ-9 score in this study was 0-24 in the vitamin D 
supplementation group and 0-22 in the placebo group. 
Table 6.1 presents the characteristics of participants stratified by treatment groups. The two 
groups had similar demographic and social-demographic features, medication uses, physical 
activity, knee symptoms, and prevalence of depression. There were also no significant 
differences in baseline characteristics, physical activity, knee symptoms and prevalence of 
depression between the consistently sufficient and not consistently sufficient groups (data not 
shown); however, the baseline serum 25(OH)D level and PHQ-9 score was higher in the 
consistently sufficient group (45.1 versus 41.5 nmol/L, P value= 0.01; 3.3 versus 2.4, P value= 
0.046). The characteristics of participants stratified by maintaining and not maintaining vitamin 
D sufficiency groups are presented in the Supplementary Table. 
 





Figure 6.1 Flowchart of the study 




Table 6.1 Baseline characteristics of participants between vitamin D supplementation and 
placebo groups 
 




Age, mean (SD), years 63.5 (6.9) 62.9 (7.2) 
Female, No. (%) 106 (52.7) 102 (50.0) 
Body mass index, mean (SD) 29.6 (5.4) 29.6 (4.6) 
Normal weight, No. (%) 42 (20.1) 23 (11.3) 
Overweight, No. (%) 88 (42.1) 90 (44.1) 
Obese, No. (%)  79 (37.8) 91 (44.6) 
Serum 25-(OH) D levels, mean (SD), nmol/L 43.7 (11.8) 43.8 (12.7) 
Regular smokers, No. (%) 92 (44.7) 98 (48.5) 
Self-reported depression, No. (%)  10 (4.8) 14 (6.9) 
Anti-depressant medicine use, No. (%) 6 (3.0) 11 (5.6) 
Physical activity   
 Insufficiently active, No. (%) 39 (22.2) 37 (20.9) 
 Sufficiently active, No. (%) 111 (63.1) 114 (64.4) 
 Highly active, No. (%) 26 (14.8) 26 (14.7) 
Highest education   
  <High school, No. (%) 26 (12.9) 25 (12.1) 
  High school, No. (%) 73 (36.1) 78 (37.7) 
  >High school, No. (%) 103 (51.0) 104 (50.2) 
WOMAC score   




  Pain (0-500), mean (SD) 137.9 (88.8) 134.7 (83.4) 
  Function (0-1700), mean (SD) 487.9 (318.1) 467.6 (292.8) 
  Stiffness (0-200), mean (SD) 61.5 (41.5) 61.7 (40.1) 
PHQ-9 score (0-27), mean (SD) 3.4 (4.1) 3.0 (4.0) 
Depression status   
  No depression, No. (%) 145 (72.1) 151 (77.0) 
  Mild depression, No. (%) 38 (18.9) 32 (16.3) 
  Moderate to severe depression, No. (%) 18 (9.0) 13 (6.6) 
PHQ-9, patient health questionnaire depression scale. 
No depression was defined as PHQ-9 scores of <5; Mild depression was defined as PHQ-9 
scores 5-9; Moderate to severe depression was defined as PHQ-9 scores of ≥10. 
Student t-test or chi2 test was used for the comparison.  
6.3.2 Vitamin D supplementation, vitamin D status and change in depressive 
symptoms 
6.3.2.1 Whole sample 
After 24 months, serum 25-(OH) D levels increased from 43.7 ± 11.8 nmol/l to 84.5 ± 17.3 
nmol/l in the vitamin D group and increased from 43.8 ± 12.7 nmol/l to 50.6 ± 17.5 nmol/l in 
the placebo group, as described previously150.  
Table 6.2 and 6.3 describe the changes in PHQ-9 scores in vitamin D treatment groups and 
vitamin D status groups. PHQ-9 scores improved more in the vitamin D supplementation group 
compared to the placebo group (β: -0.66, 95% CI: -1.22 to -0.11, Figure 2) with adjustment for 
age, sex and BMI. The results remained significant with further adjustment for baseline PHQ-
9 score, self-reported depression and usages of anti-depressant medication (β: -0.59, 95% CI: 
-1.15 to -0.04). Although the rate of obesity in the placebo group was higher than the vitamin 
D group, the results remained largely unchanged after adjustment of obesity (data not shown). 
PHQ-9 scores also improved more in those participants who maintained vitamin D sufficiency 




between month 3 and 24 compared to those who did not maintain sufficiency (β: -0.77, 95% 
CI: -1.45 to -0.08, Table 6.3 and Figure 6.3) with adjustment for potential confounders, age, 
sex, BMI, serum 25(OH)D level, PHQ-9 score, self-reported depression and usages of anti-
depressant medication at baseline. 
 
Figure 6.2 Change in PHQ-9 scores in the vitamin D supplementation group and the placebo 
group 
 
Vertical bars indicate 95% CIs for the mean scores.  
P value was for the difference between the 2 groups in PHQ-9 score changes from baseline to 
month 24.  
 











Mean (95% CI) 
Between-group 
difference change 
Mean (95% CI) 
P 
value 
Whole sample       
 Placebo Group (N= 204) 3.0 (4.0) 3.2 (3.8) 0.21(-0.19 to 0.61) 
-0.66 (-1.22 to -0.11) 0.02 
 Vitamin D Group (N= 209) 3.4 (4.1) 2.9 (3.4) -0.45(-0.84 to -0.07) 
Those without depression (PHQ-9 <5) at baseline      
 Placebo Group (N= 151) 1.3 (1.3) 2.0 (2.6) 0.66 (0.27 to 1.04) 
-0.24 (-0.79 to 0.30) 0.38 
 Vitamin D Group (N= 145) 1.4 (1.3) 1.9 (2.4) 0.41 (0.03 to 0.79) 
Those with at least mild depression (PHQ-9>=5) at baseline      
 Placebo Group (N= 45) 8.9 (4.5) 6.7 (4.6) -1.83 (-3.17 to -0.50) 
-0.86 (-2.64 to 0.91) 0.34 
 Vitamin D Group (N= 56) 8.5 (4.4) 5.4 (4.3) -2.70 (-3.86 to -1.53) 
Changes in outcomes are generated from mixed-effect models adjusted for age, sex and body mass index. Between-group differences were 
calculated by subtracting the vitamin D group values from the placebo group values.  




The differences between the vitamin D supplementation and placebo groups became smaller 
but remained significant after further adjustment for WOMAC pain (β: -0.61, 95% CI: -1.17 to 
-0.06), and WOMAC function (β: -0.59, 95% CI: -1.15 to -0.02). The differences between the 
vitamin D status groups also diminished but remained significant after further adjustment for 
WOMAC pain (β: -0.64, 95% CI: -1.24 to -0.03) but became non-significant after further 
adjustment for WOMAC function (β: -0.59, 95% CI: -1.20 to 0.03). After further adjustment 
of change in season of blood sampling, the difference between vitamin D status groups 
maintained largely unchanged (β: -0.79, 95% CI: -1.47 to -0.10). 
Figure 6.3 Change in PHQ-9 scores in the group that maintained vitamin D sufficiency 
between month 3 and 24 and the group which did not maintain vitamin D sufficiency 
between month 3 and 24 
 
Vertical bars indicate 95% CIs for the mean scores.  
P value was for the difference between the 2 groups in PHQ-9 score changes from baseline to 
month 2











Mean (95% CI) 
Between-group 
difference change 
Mean (95% CI) 
P-
value 
Whole sample       
 Not maintaining sufficient vitamin D (N= 114) 2.4 (2.9) 2.9 (3.5) 0.36 (-0.20, 0.92) 
-0.77 (-1.45, -0.08) 0.03 
 Maintaining sufficient vitamin D (N= 226) 3.3 (4.1) 2.8 (3.6) -0.41 (-0.80, -0.02) 
Those without depression (PHQ-9 <5) at baseline      
 Not maintaining sufficient vitamin D (N= 89) 1.4 (1.4) 2.0 (2.6) 0.60 (0.12, 1.08) 
-0.15 (-0.75, 0.45) 0.62 
  Maintaining sufficient vitamin D (N= 161) 1.3 (1.3) 1.8 (2.4) 0.45 (0.09, 0.80) 
Those with at least mild (PHQ-9>=5) depression at baseline      
 Not maintaining sufficient vitamin D (N= 18) 7.6 (2.9) 6.9 (3.9) -0.76 (-2.70, 1.19) 
-1.92 (4.14, 0.29) 0.09 
Maintaining sufficient vitamin D (N= 61) 8.6 (4.5) 5.9 (4.6) -2.68 (-3.74, -1.63) 
Changes in outcomes are generated from mixed-effect models adjusted for age, sex and body mass index, serum 25(OH)D level, PHQ-9 score, 
self-reported depression and usages of anti-depressant medication at baseline. Between-group differences were calculated by subtracting the 
maintaining sufficient vitamin D group values from the not maintaining sufficient group values   




6.3.2.2 Subgroup analysis by the presence of depression at baseline 
In participants with depression (PHQ-9 score ≥5) at baseline, PHQ-9 scores improved 
significantly in the vitamin D supplementation group (N= 56), placebo group (N= 45) and the 
group that maintained sufficiency between month 3 and 24 (N= 61) (Table 2 and 3). There was 
no significant change in PHQ-9 scores in the group that did not maintain sufficiency (N= 18). 
While the differences between the groups were not statistically significant, PHQ-9 scores 
improved to a greater degree in the vitamin D supplementation group (β: -0.86, 95% CI: -2.64 
to 0.91) and the group that maintained vitamin D sufficiency (β: -1.93, 95% CI: -4.14 to 0.28) 
between month 3 and 24 months compared to the placebo group and participants who did not 
maintain vitamin D deficiency, respectively. PHQ-9 scores worsened in all subgroups who did 
not suffer depression at baseline (Table 2 and 3). While there were no significant difference 
between the groups, the worsening was smaller in the vitamin D supplementation group and 
the group that maintained sufficient vitamin D between month 3 and 24.  
In the participants with moderate to severe depression  at baseline, the proportion who achieved 
MCID improvement (defined as >2.59/27) in PHQ-9 was 76.9% in the vitamin D 
supplementation group and 77.8% in the placebo group (P = 0.86). 
6.4 Discussion 
This current study, to the best of our knowledge, is the first to investigate the effect of vitamin 
D supplementation and maintaining vitamin D sufficiency on depressive symptoms over 24 
months in patients with knee OA and vitamin D deficiency. In our sample, the prevalence of 
depression in knee OA patients was 25.4%. PHQ-9 scores improved in the vitamin D treatment 
group and the group which maintained vitamin D sufficiency between month 3 and 24, 
compared to the placebo group and the group which did not maintain sufficient vitamin D, 
respectively. Clinically significant improvement in depressive symptoms did not differ 
between treatment and placebo groups. Although the improvement was small, and the clinical 
importance was uncertain, vitamin D supplementation and maintaining vitamin D sufficiency 
could reduce depressive symptoms in patients with knee OA. 




Despite the noticeable prevalence of depression in OA patients and the association between 
vitamin D deficiency and depression, no study has explored the effect of vitamin D 
supplementation on depression in OA patients. In addition, previous studies that assessed the 
effect of vitamin D supplementation on depression have not provided a consensus in the general 
population, obese or other diseased populations162. The inconsistencies among studies could 
be attributed to different study samples, different cut-offs for defining vitamin D deficiency, 
variations in the participants’ baseline and follow-up vitamin D levels, and different 
methodologies used to evaluate depression164. Some researchers provided an explanation for 
their null findings stating that they did not measure 25(OH)D levels throughout the study to 
examine if supplementation actually changed serum 25(OH)D, which was described as 
“biological flaw” and should be considered as a limitation of the study design. Some studies 
failed to demonstrate whether participants were vitamin D deficient at baseline or whether they 
achieved sufficiency during the trial162. Further RCTs are needed to address this “biological 
flaw”.  
There was a pilot study which evaluated the effect of vitamin D supplementation on depression 
in patients with chronic widespread musculoskeletal pain (CWP) and vitamin D deficiency271. 
It demonstrated that 50,000IU/week oral vitamin D3 treatment for three months resulted in a 
prominent improvement in depression, which was assessed using the 21-item Beck Depression 
Inventory (BDI) scale. In the current study, we enrolled participants with vitamin D deficiency 
at baseline, and most participants achieved vitamin D sufficiency after 24 months of treatment 
with 50,000IU monthly vitamin D3. We found that the participants reaching vitamin D 
sufficiency at month 3 were significantly more in vitamin D supplementation group than in 
placebo group150, and depressive symptoms were decreased more in vitamin D 
supplementation group from month 6. These suggest that vitamin D supplementation may have 
an effect on depressive symptoms when serum vitamin D levels reached optimal levels. 
Compared with placebo, vitamin D supplementation significantly reduced depressive 
symptoms (measured using the PHQ-9 score) in patients with knee OA in this study over 24 
months. As we hypothesized, when the vitamin D deficiency were corrected, the vitamin D 
could have the neuroprotective effect on brain. Vitamin D supplementation with daily, weekly 
or monthly dosing frequencies can achieve equally well in vitamin D sufficiency272. Therefore, 
participants receiving a daily or weekly use of same cumulative dosage could result in a similar 




outcome as receiving a monthly use. However, a monthly dosage can optimize participants’ 
adherence in long-term vitamin D supplementation study as it is more convenient. One 
weakness of our study was that we included both depressed and non-depressed participants, 
though the prevalence of depression was high in our study population compared to the general 
population aged over 65259.   
In our RCT, 62% of participants in the placebo group reached a sufficient level of serum 
25(OH)D at month 24 as reported previously, which was thought in part to result from seasonal 
variation, changes in lifestyle and dietary supplementation235. We hypothesized that the high 
proportion of patients achieving sufficient 25(OH)D levels in the placebo group would dilute 
the beneficial effects of vitamin D supplementation. Therefore, we performed a post-hoc 
analysis to describe whether maintaining sufficient serum vitamin D has a beneficial effect on 
depression. Indeed, our findings were consistent with our primary analysis, demonstrating 
maintaining sufficient serum vitamin D improved depressive symptoms. In addition, we found 
that the effects of vitamin D supplementation and maintaining serum vitamin D on depression 
remained largely unchanged after further adjustment for knee pain or function, suggesting that 
they were independent of improvements in knee symptoms.  
There is limited information regarding a MCID for the PHQ-9 scale. Lowe defined a change of 
2.59 as the MCID amongst individuals with major depression, dysthymia or both 205; thus, we 
used this value as the cut-point to define a clinically important improvement in depression. In 
those with moderate to severe depression at baseline, we did not see any difference in the rate 
of those improving by treatment groups. However, it should be noted that the prevalence of 
mild and moderate to severe depression was 17.6% and 7.8%, respectively, in this current study, 
which was considerably lower than those in OA population from previous studies 273 274, 
indicating that a few participants were clinically depressed or had major depression. Due to a 
lack of MCID for those with milder depressive symptoms, it remains unclear whether the 
statistical significant improvement in depressive symptoms we reported in this study is 
clinically important. Notably, the effect size was doubled in those with any depression at 
baseline, suggesting the potential therapeutic effect of vitamin D would be most evident in 
knee OA patients suffering from depression.  




This current study had some potential limitations. It was a secondary analysis of an RCT which 
was primarily designed to examine vitamin D supplementation on knee OA outcomes150.  
Nevertheless, this study is the first to examine the effect of vitamin D supplementation on 
depression in OA patients and the findings from this study are biologically plausible. While 
the effects were not significantly different in those with depression at baseline, most likely due 
to reduced sample size, the sizes were doubled in magnitude. It remains unclear whether the 
improvement in depressive syptoms we reported is clinically significant. Further RCTs are 
required to confirm our findings by selecting patients with both knee OA and depression. There 
may exsit unaticipanted selection bias, as baseline PHQ-9 score was higher in the group with 
maintainging vitamin D sufficiency. However, the associations remianed significant after 
adjustments for basline PHQ-9 score, suggesting the selection bias may not be a concern. In 
addition, 62% of patients in the placebo group reached sufficient vitamin D levels after 24 
months270, which might have been due to seasonal change, physical activity or other reasons. 
However, we used serum 25(OH)D levels to detect the association between variation in vitamin 
D status and depressive symptoms and obtained consistent findings. Furthermore, although the 
magnitude of the observed changes were samll, they are consistent in both parts with the RCT 
and obesevational study, suggesting the findings would be real. 
In conclusion, vitamin D supplementation and maintaining sufficient vitamin D levels over 24 






Chapter 7 Risk factors for depression in knee OA patients 
This manuscript has been submitted to “British Journal of General Practice” for review. The 
text of this chapter is the same as the submitted version. Thus, there are some repetitions of the 
methods.
  




7.1 Introduction  
Osteoarthritis (OA) is a  prevalent joint disease, characterised by whole joint structural changes, 
and is considered as “a serious disease”3. OA affects nearly 240 million people throughout the 
world, and its prevalence is projected to increase as the population ages and obesity rates 
increase275. Joint pain, stiffness and limited function are common joint symptoms of OA, 
resulting in reduced quality of life and disability that contribute to substantial financial burdens 
for individuals24. In addition, OA is associated with comorbidities, including cardiovascular 
disease, diabetes, hypertension, falls, fractures and depression3.  
Depression is a major global public health issue and is projected to be the second leading cause 
of disease burden by the year 202085 258. A systematic review and meta-analysis recently 
reported that 19.9% of people with OA had depressive symptoms, with a relative risk of 
depression of 1.17 in those with OA compared to those without86 87. However, depression is 
often under-recognised and under-treated in older adults, particularly in patients with OA259 276. 
Furthermore,  concomitant depression in OA patients contributes to increased difficulties in 
OA management and disease burden85. Therefore, the interaction between OA and depression 
should be taken seriously, and screening, prevention and treatment of depression in OA patients 
should be considered277.   
Concomitant depression with OA may be mediated by either biological or behavioural 
mechanisms with different aetiology and risk factors85 278. A better understanding of depression 
in OA patients is crucial for identifying modifiable risk factors and key areas for intervention3. 
Joint pain, decreased physical performance and increased risks for chronic comorbidities are 
typical characteristics of OA, which may be associated with depression259 274 279; however, the 
longitudinal relationship between clinical OA characteristics and depression in individuals 
with OA has been poorly studied. In addition, although the reciprocal relationship between 
depression severity and pain is established, whether current depression severity predicts 
changes in joint symptoms overtime has been rarely investigated in knee OA patients280-282. 
The aims of this study were, therefore, to describe demographic and clinical factors associated 
with the prevalence and incidence of depression and to explore the temporal relationship 
between depression and joint symptoms in patients with symptomatic knee OA.  





7.2.1 Study design and participants  
This study is a post-hoc analysis of the Vitamin D Effect on Osteoarthritis (VIDEO) study, 
which was a multicenter, randomized, double-blind, placebo-controlled trial to evaluate the 
effect of vitamin D supplementation in patients with symptomatic knee OA and vitamin D 
deficiency175. Participants were allocated to either the vitamin D or placebo arm at a ratio of 
1:1 and received 50,000IU (1.25mg) vitamin D3 (cholecalciferol) monthly for 24 months 
(treatment group) or identical inert placebo (placebo group)175. In this current study, both 
treatment and placebo groups were combined as a cohort.  
Participants with symptomatic knee OA for at least 6 months, which was assessed according 
to the American College of Rheumatology (ACR) criteria18, with knee pain of >20 mm on a 
100-mm visual analog scale (VAS) and low levels of 25-hydroxyvitamin D [25(OH)D, 
between 12.5 and 60 nmol/L] were enrolled in Tasmania and Victoria, Australia175. Participants 
with the severe radiographic changes (grade 3 on the Altman and Gold atlas), severe knee pain 
on standing (>80 mm on a 100-mm VAS), other rheumatic diseases, contraindication to MRI, 
cancer, severe cardiac or renal impairment, hypersensitivity to vitamin D, anticipated knee or 
hip surgery within the next 2 years and history of taking vitamin D within the previous 1 month 
were excluded from this study.  
The study was approved by the Tasmania Health and Human Medical Research Ethics 
Committee (reference number H1040) and Monash University Human Research Ethics 
Committee (reference number CF10/1182-2010000616). Informed written consent was 
obtained from all participants.  
7.2.2 Measurements of depression severity   
Depression severity was measured using the patient health questionnaire (PHQ-9) at baseline 
and 24 months. PHQ-9 is a valid and reliable instrument, which is widely used in diagnosing 
and assessing the severity of depression205. It is a nine-item depression questionnaire with a 
score range of 0 to 27, with each item being scored from 0 (not at all) to 3 (nearly every day). 
Using the mental health professional interview as the criterion standard, a cut-off point of ≥5 




has a sensitivity of 81.5% and a specificity of 80.6% for mild depression and a cut-off point of 
≥10 has a sensitivity of 54.3% and a specificity of 91.1% for moderate or severe depression283.  
7.2.3 Anthropometrics and social demographic characteristics  
Height was measured to the nearest 0.1 cm (with shoes removed) using a stadiometer (Leicester 
Height Measure, Invicta Plastics Ltd, Leicester, UK). Weight was measured to the nearest 0.1 
kg (with shoes and bulky clothing removed) using electronic scales (Heine S-7307, Heine, New 
Hampshire, USA). Body mass index (BMI, in kg/m2) was calculated175.  
Patients filled out a questionnaire which collected information on education history (grade 0: 
less than high school, grade 1: high school degree and grade 2: superior than high school 
degree), current smoking (yes or no) and concomitant medication usage.  
7.2.4 Knee joint symptoms measurement 
Knee joint symptoms were assessed at baseline and month 24 using the Western Ontario and 
McMaster Universities OA Index (WOMAC), which is widely used to evaluate the functional 
capacity in patients with OA with high performance in clinical trials 183. The Index contains 24 
questions, 5 related to pain, 2 to stiffness and 17 to physical function, with scores from 0 (none) 
to 100 (severe). The total WOMAC score (0-2400) is the sum of subscale scores including pain 
(0-500), stiffness (0-200) and physical function (0-1700).  
7.2.5 Knee joint radiographic measurement   
Radiographic OA was assessed at baseline using a standing semi-flexed anterior-posterior (AP) 
radiograph as per the Altman atlas178. Radiographs were assessed simultaneously by two 
observers using the Altman atlas to score osteophytes and joint space narrowing on a four-point 
scale (0 to 3) at medial tibial, lateral tibial, medial femoral and lateral femoral sites. The 
presence of radiographic OA was defined as any score of ³ 1 for JSN or osteophytes. 
7.2.6 Physical activity  




Physical activity was assessed at baseline and month 24 as steps/day determined by pedometer 
(SW200 Digi-Walker, Yamax Corporation, Tokyo, Japan)175. Briefly, participants were 
instructed to wear a pedometer for 7 consecutive days from the time they woke up until they 
went to bed and to record the number of steps each day and the duration and type of physical 
activity for any activities in which the pedometer could not be worn (for example, swimming). 
Mean steps/day were calculated as the average of the days worn at both time points202.  
7.2.7 Multi-sites pain 
The location of sites at which the participants experienced pain was self-reported at baseline. 
Participants were asked whether they had pain (yes/no) in the following sites: neck, lower back, 
hands, shoulders and others. The total number of painful sites (range 0 to 5) was categorized 
into 3 groups (no pain, one painful site, two or more painful sites) according to the number of 
painful site groups.  
7.2.8 Self-reported medical conditions   
Participants were asked whether they have been told by a doctor or a nurse that they had (yes/no) 
any of the following conditions: depression, angina, high blood pressure, heart attack, stroke, 
high cholesterol, diabetes, osteoporosis, asthma, bronchitis and emphysema, and whether they 
had these conditions currently. The total number of current comorbidities, except for 
depression, was categorized into three groups (no comorbidity, one comorbidity and two or 
more comorbidities).  
7.2.9 Data analyses  
Baseline characteristics are described as mean ± standard deviation (SD) or numbers of 
participants (percentage). Univariable and multivariable log-binomial regressions were used to 
explore risk factors associated with the prevalence of depression at baseline and incidence of 
depression over time. If the log-binomial model failed to converge, it was estimated by using 
a Poisson distribution and robust standard errors. Multivariable models for prevalent 
depression were adjusted for age, sex, BMI and baseline vitamin D level. Multivariable models 
for incident depression were adjusted for age, sex, BMI, baseline 25(OH)D level and treatment 




arms (vitamin D treatment versus placebo). Univariable and multivariable linear regressions 
were used to examine the temporal relationship between baseline depressive symptoms and 
change in knee symptoms over 24 months before and after adjustment for age, sex, BMI, 
baseline 25(OH)D level, treatment arms and baseline WOMAC score. All tests were two-sided 
and a P value of <0.05 was considered statistically significant. Stata version 12.0 was used to 
perform statistical analyses. 
7.3 Results   
7.3.1 Baseline characteristics of participants  
Table 7.1 presents baseline characteristics of the study participants. The mean age of 413 
participants was 63.2 ± 7.0 years and mean BMI was 29.6 ± 5.0. Of them, 208 (50.4%) 
participants were female and 209 (50.6%) were allocated to the treatment group. At baseline, 
296 (74.6%) participants were identified as not suffering from depression, 70 (17.6%) were 
identified as suffering from mild depression, and 31 (7.8%) were identified as suffering from 
moderate to severe depression. The prevalence of any depression in this study was 25.4% 
(according to the PHQ-9), 5.8% of participants had self-reported depression and 4.3% used 
anti-depressant medications. 





Age (years) 63.2 7.0 
Female sex (n, %) 208 50.4 
Body mass index (kg/m2) 29.6 5.0 
Serum 25-(OH)D levels (nmol/L) 43.8 12.2 
PHQ score    
 0-4 296 74.6 




 5-9 70 17.6 
 ≥ 10  31 7.8 
Anti-depressant medication use (n, %) 17 4.3 
Physical activity, (1000 step/day) 7.4 3.4 
Education   
 School only (n, %) 51 16.3 
 High school (n, %) 101 32.3 
 University or higher (n, %) 161 51.4 
Radiographic osteoarthritis (n, %) 339 96.0 
WOMAC score   
 Pain (0-500) 136.3 86.1 
 Function (0-1700) 478.0 305.8 
 Stiffness (0-200) 57.4 16.6 
Multi-site joint pain, (n, %)   
 No pain  252 61.0 
 One site  136 32.9 
 More than one site  25 6.1 
Comorbidity, (n, %)   
 No comorbidity  170 41.2 
 One comorbidity  229 55.5 
 More than one comorbidity  14 3.4 
PHQ-9, patient health questionnaire depression scale. 
  




7.3.2 Factors associated with the prevalence of depression  
As shown in Table 7.2, being female, and having a higher BMI, greater scores of WOMAC 
pain (Figure 7.1 A), WOMAC function (Figure 7.1 B) and WOMAC stiffness, a lower 
education level, and one more comorbidity were significantly associated with a higher 
prevalence of depression in univariable analyses. After adjustment for age, sex, BMI and 
baseline 25-(OH)D level, the associations persisted except for female sex, which was no longer 
statistically significant. Having two or more sites pain appeared to be significantly associated 
with higher prevalence of depression in multivariable analyses. Age and radiographic OA were 
not significantly associated with the prevalence of depression in either univariable or 
multivariable analysis. Results were similar, when self-reported depression was used as the 
outcome or if the analyses were adjusted for anti-depressant medication use (data not shown). 
Table 7.2 Factors associated with the prevalence of mild to severe depression at baseline 
 Univariable  Multivariable* 
PR (95% CI) PR (95% CI) 
Age (years)  0.99 (0.98, 1.01) 0.96 (0.94, 0.99) 
Female sex (n, %)  1.55 (1.10, 2.18) 1.38 (0.98, 1.96) 
BMI (kg/m2)  1.06 (1.03, 1.09) 1.05 (1.02, 1.08) 
Physical activity, (1000 steps/day) 0.96 (0.92, 1.01) 0.96 (0.90, 1.03) 
Education   
 School only (n, %) Reference  Reference 
 High school (n, %) 0.63 (0.40, 1.00) 0.61 (0.40, 0.95) 
 University or higher (n, %) 0.47 (0.30, 0.73) 0.50 (0.34, 0.74) 
Radiographic osteoarthritis (n, %) 0.98 (0.94, 1.02) 0.98 (0.94, 1.02) 
WOMAC score/ 10 unit   
 Pain (0-50) 1.04 (1.03, 1.07) 1.05 (1.03, 1.07) 




 Function (0-170) 1.02 (1.01, 1.02) 1.02 (1.01, 1.02) 
 Stiffness (0-20) 1.07 (1.04, 1.11) 1.05 (1.02, 1.09) 
Multi-site joint pain, (n, %)   
 No pain  Reference Reference 
 One site  1.21 (0.85, 1.74) 1.06 (0.75, 1.51) 
 More than one site  1.64 (0.93, 2.88) 1.73 (1.01, 2.98) 
Comorbidity, (n, %)   
 No comorbidity  Reference Reference 
 One comorbidity  1.08 (0.75, 1.55) 1.14 (0.80, 1.65) 
 More than one comorbidity  2.13 (1.18, 3.86) 1.98 (1.03, 3.80) 
Mild to severe depression was defined as PHQ-9 scores ≥ 5.  
*All multivariable analyses were adjusted for age, sex, BMI and baseline 25-(OH)D level, 
except for age (adjusted for sex, BMI and baseline 25-(OH)D level), sex (adjusted for age, BMI 
and baseline 25-(OH)D level) and BMI (adjusted for age, sex and baseline 25-(OH)D level). 
 
7.3.3 Factors associated with incidence of depression  
340 participants completed the follow-up. 28 out of 249 participants (11.2%) without 
depression at baseline reported having incident mild to severe depression at 24 months. Table 
7.3 shows the factors associated with incident depression over 24 months. Being female and 
having a higher WOMAC pain (Figure 7.1 C) and WOMAC function (Figure 7.1 D) score 
were significantly associated with greater incident depression over 24 months in the univariable 
and multivariable analyses. Having two or more painful sites was significantly associated with 
greater incident depression over 24 months in the multivariable analyses. In a sensitivity 
analysis further adjusting for anti-depressant medication, the results were largely unchanged 
(data not shown). In contrast, there were no significant associations between age, BMI, 




physical activity, education, radiographic OA, WOMAC stiffness, comorbidity and incident 
depression.  
Table 7.3 Factors associated with the incidence of mild to severe depression at 24 months 
amongst participants without depression at baseline 
 Univariable Multivariable* 
RR (95% CI) RR (95% CI) 
Age (years)  0.99 (0.94, 1.04) 1.00 (0.96, 1.05) 
Female sex (n, %)  2.23 (1.06, 4.66) 2.33 (1.09, 4.95) 
Body mass index (kg/m2)  0.98 (0.91, 1.06) 0.98 (0.91, 1.06) 
Physical activity, (steps/day) 1.01 (0.90, 1.13) 0.99 (0.87, 1.12) 
Education   
 School only (n, %) Reference  Reference 
 High school (n, %) 0.86 (0.24, 3.10) 0.81 (0.22, 2.94) 
 University or higher (n, %) 0.89 (0.28, 2.82) 0.89 (0.28, 2.84) 
Radiographic osteoarthritis (n, %) 0.92 (0.84, 1.01) 0.93 (0.85, 1.02) 
WOMAC score/ 10 unit   
 Pain (0-50) 1.04 (1.00, 1.08) 1.04 (1.00, 1.08) 
 Function (0-170) 1.01 (1.00, 1.02) 1.01 (1.00, 1.02) 
 Stiffness (0-20) 1.01 (0.93, 1.11) 1.01 (0.93, 1.10) 
Multi-site joint pain, (n, %)   
 No pain  Reference  Reference 
 One site  1.30 (0.61, 2.75) 1.13 (0.53, 2.42) 
 More than one site  2.17 (0.69, 6.80) 3.63 (1.04, 12.7) 
Comorbidity, (n, %)   




 No comorbidity  Reference  Reference 
 One comorbidity  0.93 (0.45, 1.91) 1.01 (0.48, 2.14) 
 More than one comorbidity  1.12 (0.16, 7.68) 0.97 (0.14, 6.87) 
Mild to severe depression was defined as PHQ-9 scores ≥ 5. 
*All multivariable analyses were adjusted for age, sex, BMI and baseline 25-(OH)D level, 
except for age (adjusted for sex, BMI and baseline 25-(OH)D level), sex (adjusted for age, BMI 
and baseline 25-(OH)D level) and BMI (adjusted for age, sex and baseline 25-(OH)D level). 
Figure 7.1 Associations of baseline WOMAC pain (0-500) and WOMAC function (0-1700) 
tertiles with the prevalence (A, B) and incidence (C, D) of depression in patients with knee 
OA 
 




7.3.4 Temporal relationship between baseline depression and changes in joint 
symptoms overtime 
Table 7.4 describes the longitudinal association of baseline depression with changes in knee 
joint symptoms over 24 months. Although participants with mild to severe depression had 
greater decreases in WOMAC symptoms compared to participants without depression at 
baseline in the univariable analyses, the significant associations disappeared in the 
multivariable analyses. In addition, the results were consistent when either self-reported 
depression at baseline was used as the exposure or if the analyses were adjusted for anti-
depressant medication use (data not shown). 
Table 7.4 The association between depression severity at baseline and change in joint 
symptom over 24 months 
 
Univariable 
β (95% CI) 
Multivariable 
β (95% CI) 
WOMAC Pain (0-500) †   
 No depression  Reference  Reference 
 Mild depression  -35.8 (-63.7, -7.9) -12.4 (-36.7, 11.8) 
 Moderate to severe depression  -100.3 (-143.1, -57.4) -32.0 (-72.2, 8.2) 
WOMAC Function (0-1700) ‡   
 No depression  Reference Reference 
 Mild depression  -139.9 (-222.2, -57.7) -67.8 (-145.4, 9.7) 
 Moderate to severe depression  -225.4 (-357.5, -93.2) -90.3 (-220.3, 39.7) 
WOMAC Stiffness (0-200) §   
 No depression  Reference Reference 
 Mild depression  -13.2 (-26.0, -0.5) -5.2 (-16.5, 6.1) 
 Moderate to severe depression  -29.4 (-49.0, -9.8) -11.8 (-30.0, 6.5) 




† Multivariable analysis was adjusted for age, sex, BMI, baseline 25-(OH)D level, treatment 
arm and baseline WOMAC pain score.  
‡ Multivariable analysis was adjusted for age, sex, BMI, baseline 25-(OH)D level, treatment 
arm and baseline WOMAC function score.  
§ Multivariable analysis was adjusted for age, sex, BMI, baseline 25-(OH)D level, treatment 
arm and baseline WOMAC stiffness score.  
7.4 Discussion 
This study investigated the temporal relationships between demographic and OA clinical 
factors, joint symptoms and depression in patients with symptomatic knee OA. Depression was 
common in this population with a prevalence of 25.4% and incidence of 11.2% over 24 months. 
Common OA risk factors such as higher BMI, lower education level and having two or more 
comorbidities were associated with prevalent depression and being female was associated with 
incident depression in knee OA patients. Higher levels of knee pain and physical dysfunction 
and having multi-site pain were associated with increased risks of both prevalent and incident 
depression. In contrast, baseline depression severity did not predict changes in OA symptoms. 
These findings suggest that treatment of depression in OA may not necessarily lead to 
improvements in knee symptoms in knee OA patients. 
Numerous studies have explored the demographic factors associated with depression in elderly 
populations. Female sex, lower education levels and the biological risks including endocrine 
and inflammatory factors are potential risk factors for depression in the elderly284. However, 
only a few studies have been conducted in individuals with OA, and most did not assess 
longitudinal relationships. A cross-sectional study reported that fewer social contacts, 
increased BMI, perceived pain and limited physical activity were associated with depression 
severity in 1021 patients with knee OA274. In our current study, we reported similar results and 
reported that, cross-sectionally, higher BMI, lower education level and having two or more 
comorbidities were associated with prevalent depression.  
Obesity, female sex and a lower education level are known as risk factors for both OA and 
depression. Therefore, the high prevalence of depression in OA individuals may be in part 




attributed to shared risk factors. Taking higher BMI for example, higher BMI, indicating 
overweight or obesity, is a well-known risk factor of OA and also can increase vulnerability to 
depression directly and indirectly through complex mechanisms285 286. Obesity causes a high 
prevalence of OA, which may be related to combined effects from biomechanical, 
inflammatory and metabolic factors. In addition, obesity can induce poor self-image, low self-
esteem and social isolation, which are well-known contributors to depression. It also can 
activate inflammatory pathways, involving hypothalamic-pituitary-adrenal axis dysregulation, 
which are associated with increased risk of depression through biological and psychological 
pathways285. Obesity and lower levels of education are modifiable factors; therefore, 
management of obesity and improvement of education level may prevent depression and 
should have beneficial effects in patients with knee OA. Additionally, female sex predicted 
incident depression over 24 months in knee OA patients. Hence, it is important for clinicians 
to screen for, and try to prevent and treat depression, especially in female patients with knee 
OA.  
Joint pain and dysfunction, multisite pain and comorbidities are clinical characteristics of OA. 
Multisite pain, joint pain and joint function limitation are common in musculoskeletal 
conditions, and have been linked to depression in previous studies287. Individuals who 
experienced chronic pain and physical activity limitation are at an increased risk of 
depression288 289. In OA patients, joint pain severity and dysfunction were associated with 
depression severity cross-sectionally and longitudinally290-295. Knee OA patients with greater 
pain associated with higher risk of depression at baseline and slow gait speed may represent an 
important risk factor for worsening depressive symptoms over time293 295. In our study, 
although we used a different method to assess depression severity, we found similar results. 
Individuals who experienced multi-site pain, more severe knee pain and joint dysfunction, and 
had more than one comorbidity were at a higher risk of prevalent depression cross-sectionally 
in knee OA patients. Over 24 months, multi-site pain, knee pain and dysfunction were 
associated with increased incidence of depression over 24 months, suggesting a potential causal 
relationship. These supported the notion that management of pain, joint dysfunction and other 
comorbidities may help to improve depression in knee OA patients281 296. 




Depression severity is dynamic, changing over time, and prior depressive illness modifies the 
experience of currently depressed mood297. The reciprocal relationship between depression 
severity and pain severity has been well established, but whether current depression severity 
has causal effects on severity of joint symptoms overtime has been rarely investigated280 282. 
Kurt et al have reported that change in pain severity over 3 months predicted subsequent 
depression severity, and vice versa, change in depression severity over 3 months predicted 
subsequent pain severity over 12 months in patients with persistent back, hip and knee pain280. 
In knee OA patient, we only found higher levels of knee joint symptoms and having multi-site 
pain at baseline were associated with increased risks of both prevalent and incident depression, 
while baseline depression severity did not predict knee joint symptomatic progression over two 
years. There was one study have explored the causal cumulative effect between depressive 
symptoms and knee pain among patients with knee radiographic OA. Rathbun reported the 
causal effect of pain severity significantly increases with the persistence of depressed mood, 
but depressive symptoms on OA knee pain does not change over time, which was smiliar with 
this current study282. Our findings suggest the potentially cause-effect relationship is from knee 
joint pain and physical dysfunction to depression, rather than from depression to knee 
symptoms, in patients with knee OA.  
This study has some potential limitations. It was a post-hoc analysis of an RCT which was 
primarily designed to examine vitamin D supplementation on knee OA outcomes.  
Nevertheless, the findings from this study were plausible as we found that vitamin D 
supplementation reduced visual analog scale knee pain, improved physical function and 
decreased depressive symptoms150 298. The effects on depressive symptoms may be mediated 
through the effects on knee pain and physical function. In addition, 18% participants did not 
complete the 24 months follow-up, and loss of follow-up bias may be present; however, the 
retention rate in this trial was high, and there were no significant differences in the baseline 
characteristics between those who completed and who did not complete the trial. This suggests 
a minimal loss of follow-up bias in our study. Furthermore, we defined depression using the 
patient health questionnaire, which was developed for depression diagnostic, severity measures 
and assessment of depression outcome changes over time. It may lead to misclassification of 
depression; however, when we used the self-reported depression as the outcome or exposure 
and anti-depressant medication as a covariate and the results were largely unchanged.  




In summary, knee OA risk factors and joint symptoms, along with co-existing multi-site pain 
are associated with the prevalence and development of depression. This provide empirical 
evidence that managing common OA risk factors and joint symptoms could be important for 






Chapter 8 Effects of vitamin D on foot pain 
This manuscript has been submitted to “Seminars in Arthritis and Rheumatism” for review. 
The text of this chapter is the same as the submitted version. Thus, there are some repetitions 
of the methods.
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8.1 Introduction  
Osteoarthritis (OA) is a highly prevalent chronic joint disease worldwide characterized by joint 
pain and deformity. The knee is the most common affected joint and is often associated with 
dsiabilty22. In those over 60 years old, the global prevalence of symptomatic knee OA is 
approximately 10% in men and 13% in women1, and the prevalence of knee OA has estimately 
doubled since the mid-20th century299, and  the financial burden is estimated as high as 1.0%-
2.5% of the GDP in Western countries300. Although there have been effective agents that can 
relieve pain and improve function, there are no treatments showing significant disease-
modifying effects on OA disease progression301 302. More important, in older adults, 
comorbidity for OA was prevalent, with musculoskeletal as well as non-musculoskeletal 
conditions83.  
Foot pain, a common musculoskeletal pain, affects nearly one in five older people in the 
community and has a detrimental impact on health-related quality of life91 92 96 208 303. Foot pain 
often coexists with knee pain, further impairing physical activity, quality of life and increased 
levels of depression in knee OA patients than in the general population93 96. Moreover, foot 
pain is a prevalent commorbidty in knee OA patients. In the OA initiative cohort study, 25% 
knee OA patient reported occurrent foot pain93. A survey of 8990 older people has 
demonstrated most people with knee pain had multiple joint site pain, and the severity of knee 
pain and related disability were worse in the presence of pain elsewhere304. Given that patients 
with knee OA are more likely to have more severe foot pain and foot pain often lead to even 
worse physical activity and lower quality of life in knee OA patients, management of foot pain 
in OA patients is of priority. 
Previous epidemiological studies reported that vitamin D deficiency was associated with 
chronic musculoskeletal pain and depression, but underlying mechanisms were complex and 
unclear159 167 305. Studies exploring the effect of vitamin D supplementation on non-specific 
chronic pain in the adult population and those with rheumatoid arthritis and osteoporosis have 
had inconsistent findings167 306. To date, there have been no studies exploring the effect of 
vitamin D supplementation on foot pain in knee OA patients. Therefore, our study aims to 
explore whether vitamin D supplementation or maintaining sufficient vitamin D level reduces 
foot pain in patients with symptomatic knee OA, initially with lower vitamin D status. 
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8.2 Methods 
8.2.1 Participants and trial design 
A post hoc study was conducted from a randomized double-blind placebo-controlled trial 
named the Vitamin D Effect on Osteoarthritis (VIDEO) study, in which the primary outcomes 
were tibial cartilage volume and knee pain among patients with symptomatic knee OA307. 
Patients who suffered from symptomatic knee OA at least for 6 months, had knee pain of 20-
80 mm on a 100-mm visual analog scale (VAS) and serum 25-hydroxyvitamin D levels 
between 12.5 nmol/L to 60 nmol/L, and aged 50 to 79 years were included. Patients with the 
Altman and Gold atlas grade 3 radiographic changes, severe knee pain on standing (>80 mm 
on a 100-mm VAS), other rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis 
and lupus, contraindication to MRI, cancer, severe cardiac or renal impairment, 
hypersensitivity to vitamin D, anticipated knee or hip surgery within the next 2 years and 
history of taking vitamin D within the previous 1 month were excluded from this study. After 
signing the written consent, patients were randomly allocated to 24 months’ vitamin D or 
placebo treatment at a ratio of 1:1. A monthly capsule containing 50000IU (1.25mg) vitamin 
D3 (cholecalciferol) or placebo was given to patients and assessments were conducted at 
baseline and at month 3, 6, 12 and 24.  
8.2.2 Measurements  
8.2.2.1 Manchester Foot Pain and Disability Index Questionnaires  
Manchester Foot Pain and Disability Index (MFPDI) questionnaire was used to measure foot 
pain of patients at month 0, 3, 6, 12 and 24. MFPDI was developed to measure foot pain and 
disability in the elderly308. Each item was scored either 1 (none of the time), 2 (on some days) 
or 3 (on most days/every day). The total score was calculated by summing the scores of 17 
items and higher score indicated greater disability. Four subscales were calculated including 
functional limitation (items 2-8), pain intensity (items 10-11, 14-17), concern about appearance 
(items 12-13) and activity restriction (items 1 and 9)208. It has been proven to be a useful and 
valid instrument of assessing foot pain in the older population and was used in both 
observational studies and randomized controlled trials309. Disabling foot pain was defined 
when at least one of the 10 functional limitation items (items 1-9,11) being documented as on 
‘most/every day(s)’ in the last month309.  
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8.2.2.2 Knee structures measurements 
Radiographic OA was assessed at baseline by a standing semiflexed anterior-posterior 
radiograph as per the Altman atlas177 according to the protocol using the Osteoarthritis 
Research Society International (OARSI) atlas to score osteophytes and joint space narrowing. 
MRI scans with a commercial transmit-receive extremity coil at baseline and two years of the 
study knee were obtained according to a standardized protocol. T2-weighted/proton density-
weighted fast spin echo sequences were used to assess cartilage defects and bone marrow 
lesions (BMLs) and detail are described before in the protocol310.  
8.2.2.3 Knee symptoms measurements  
Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC)183 scale was used 
to detect knee symptoms at month 0, 3, 6, 12 and 24. The sum of pain (0-500), stiffness (0-200) 
and physical function (0-1700) subscales is calculated as the total WOMAC score (0-2400). 
8.2.2.4 Serum 25(OH)D measurement and definition of vitamin D status 
Serum 25-hydroxyvitamin D levels were assayed using direct competitive chemiluminescent 
immunoassays at screening, month 3 and month 24. Patients whose serum 25-hydroxyvitamin 
D level greater than 50 nmol/L at both month 3 and 24 were classified into maintaining 
sufficient vitamin D group and whose serum 25-hydroxyvitamin D level less than 50 nmol/L 
at either month 3 and 24 were classified into not maintaining sufficient vitamin D group. 
8.2.2.5 Other measurements 
Body height and weight were measured at baseline and body mass index (BMI, in kg/m2) was 
calculated. Height was measured to the nearest 0.1 cm (with shoes removed) using a 
stadiometer (Leicester Height Measure, Invicta Plastics Ltd, Leicester, UK) and weight was 
measured to the nearest 0.1 kg (with shoes and bulky clothing removed) using electronic scales 
(Heine S-7307, Heine, New Hampshire, USA).  
8.2.3 Statistical analysis 
Baseline characteristics between patients with and without disabling foot pain were compared 
using independent t or χ2 tests. A repeated-measure mixed effect model with terms for 
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treatment, time, treatment by time and adjustment for age, sex, BMI was used to analyse the 
change in MFPDI scores over 24 months between groups including vitamin D vs. placebo 
group and maintaining sufficient vitamin D vs. not maintaining sufficient vitamin D group. 
Multilevel mixed-effect models were used to deal with missing data caused by loss to follow-
up and nonresponses. Subgroup analysis exploring effects of vitamin D supplementation and 
maintaining sufficient vitamin D level on foot pain relief in patients with disabling foot pain at 
baseline was performed. All tests were two-sided and P value <0.05 was considered statistically 
significant. Stata version 12.0 was used to perform statistical analyses. 
8.3 Results 
8.3.1 Baseline characteristics  
A total of 413 patients were included and randomized to receive either vitamin D (n=209) or 
placebo (n=204) treatment. After 24 months, 340 patients completed the trial and no significant 
differences in baseline characteristics were found between patients who completed the study 
and who did not. The average age of patients was 63.2 years with a mean BMI of 29.6, and 
49.7% of them were female. The mean MFPDI score was 22.8±7.3. For those reported foot 
pain (n=214, 51.8%) at baseline, 74 (34.6%) reported pain in the toes, 49 (22.9%) reported pain 
in the ball of foot, 48 (22.4%) reported pain in the arch, 43 (20%) reported in whole feet and 
37 (17.3%) reported pain in heel. 23.7% (n=98) of patients were found to have disabling foot 
pain according to the MFPDI case definition. There were also no significant differences in 
baseline characteristics, MFPDI scores, prevalence of disabling foot pain, knee symptoms and 
knee structure measurements between vitamin D group and placebo group (Table 1). At the 
same time, the baseline vitamin D level was higher in the maintaining sufficient vitamin D 
group compared with not maintaining sufficient vitamin D group (45.2 vs 41.5, P=0.01) while 
no significant differences were found between groups in other characteristics. 
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Table 8.1 Baseline characteristics of participants between maintaining sufficient vitamin D 
group and insufficient vitamin D group 






Age, mean (SD), years 63.6 (6.9) 62.6 (7.2) 0.32 
Female, No. (%) 106 (50.7) 102 (50) 0.92 
Body mass index, mean (SD),kg/m2 29.6 (5.4) 29.6 (4.6) 0.88 
Serum 25-(OH) D levels, mean (SD), nmol/L 43.7 (11.8) 43.8 (12.7) 0.95 
MFPDI (0-34), mean (SD) 21.6 (6.8) 22.7 (7.5) 0.27 
Disabling foot pain, No. (%) 101 (47.4) 112 (52.6) 0.30 
AQOL (0-1), mean (SD) 0.74 (0.17) 0.75 (0.18) 0.69 
*Depression, No. (%)  56 (27.9) 45 (23.0) 0.26 
WOMAC score    
Pain (0-500), mean (SD) 137.9 (88.8) 134.7 (83.4) 0.71 
Function (0-1700), mean (SD) 487.9 (318.1) 467.6 (292.8) 0.50 
Stiffness (0-200), mean (SD) 61.5 (41.5) 61.7 (40.1) 0.95 
Knee structures    
Total radiographic OA (0-18) 8.3 (5.6) 8.3 (4.9) 0.93 
Total cartilage defects (0-24) 14.8 (4.1) 14.4 (3.9) 0.29 
Total bone marrow lesions (0-45) 3.2 (3.2) 3.6 (3.2) 0.17 
MFPDI, Manchester foot pain and disability index; AQoL, assessment of quality of life. 
Depression was defined as PHQ-9 score of ≥5. 
Two-tailed Student’s t-tests were used for differences between means. 
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!2 tests were used for proportions (percentages) and Wilcoxon rank-sum tests were used for 
differences between medians.  
8.3.2 Vitamin D supplementation and change in MFPDI scores  
Over 24 months, MFPDI scores remained largely unchanged in the vitamin D group (β: -
0.03, 95% CI: -0.80 to 0.74) while worsened in the placebo group (β: 1.30, 95% CI: 0.51 to 
2.09) (Figure 8.1), and there were significant differences in change of MFPDI scores between 
groups in the mixed-effect model after including all time points adjusted for age, sex and BMI 
(-0.03 in vitamin D group vs. 1.30 in placebo group; between-group difference, β: -1.32, 95% 
CI: -2.43 to -0.22, P= 0.013) (Table 8.2 and Figure 8.1). 
In subgroup analyses, for patients with disabling foot pain at baseline, although those who 
received vitamin D treatment (β: -4.86, 95% CI: -6.79 to -2.93) had greater reduction in 
MFPDI scores compared with placebo group (β: -2.30, 95% CI: -5.33 to -0.31) after 24 
months, no significant difference between groups was found (β: -2.56, 95% CI: 5.33 to 0.21, 
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Figure 8.1 Change in MFPDI scores in the vitamin D supplementation group and the placebo 
group 
 
Vertical bars indicate 95% CIs for the mean scores.  
P value was for the difference between the 2 groups in MFPDI score changes from baseline to 
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Table 8.2 Effect of vitamin D supplementation on change in MFDPI over two years 
 
Mean change 
Mean (95% CI) 
Between-group difference change 
Mean (95% CI) 
P 
value 
Whole sample     
Placebo Group (N= 204) 1.30 (0.51, 2.09) 
-1.32 (-2.43, -0.22) 0.013 
Vitamin D Group (N= 209) -0.03 (-0.80, 0.74) 
Those without disabling foot pain at baseline    
Placebo Group (N= 153) 2.46 (1.66, 3.25) 
-1.09 (-2.20, 0.02) 0.05 
Vitamin D Group (N=162) 1.36 (0.59, 2.14) 
Those with disabling foot pain at baseline    
Placebo Group (N=51) -2.30 (-5.33, -0.31) 
-2.56 (-5.33, 0.21) 0.07 
Vitamin D Group (N=47) -4.86 (-6.79, -2.93) 
Changes in outcomes are generated from mixed-effect models adjusted for age, sex and body mass index. Between-group differences were 
calculated with vitamin D group values minus placebo group values.  
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8.3.3 Maintaining sufficient vitamin D levels and change in MFPDI scores  
Post-hoc analyses comparing patients who maintained sufficient vitamin D with who did not 
maintain vitamin D sufficiency showed that MFPDI score decreased in those maintaining 
sufficient vitamin D group (β: -0.09, 95%CI: -0.79 to 0.61) while increased in those not 
maintaining sufficient vitamin D group (β: 2.19, 95%CI: 1.21 to 3.81) over 2 years (between-
group difference, β: -2.29, 95%CI:  -3.49 to -1.08, P=0.001) after adjusted for age, sex, BMI, 
serum 25(OH)D level and baseline MFPDI score (Table 8.3 and Figure 8.2). The results 
maintained largely unchanged after further adjustment for the change in season of blood 
sampling (β: -2.30, 95% CI: -3.52 to -1.10). 
In subgroup analyses, for those with disabling foot pain at baseline, there was a greater decrease 
in MFPDI score in those maintaining sufficient vitamin D group (β: -4.63, 95% CI: -6.35 to -
2.92) compared to those not maintaining sufficient vitamin D group (β: -0.14, 95% CI: -2.75 
to 2.48) and between-group difference (β: -4.49, 95% CI: -7.62 to -1.37, P= 0.005) was 
significant, as shown in Table 8.3. There were similar findings in patients without disabling 
foot pain at baseline (Table 8.3).  
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Figure 8.2 Change in MFPDI scores in the group that maintained vitamin D sufficiency 
between month 3 and 24 and the group which did not maintain vitamin D sufficiency 
between month 3 and 24 
 
Vertical bars indicate 95% CIs for the mean scores.  
P value was for the difference between the 2 groups in MFPDI score changes from baseline to 
month 24.  
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Table 8.3 Effect of vitamin D status on change in MFDPI over 2 years 
 
Mean change 
Mean (95% CI) 
Between-group difference change 
Mean (95% CI) 
P 
value 
Whole sample     
Insufficient vitamin D (N= 114) 2.19 (1.21 to 3.18) 
-2.29 (-3.49 to -1.08) 0.001 
Maintaining sufficient vitamin D (N= 226) -0.09 (-0.79 to 0.61) 
Those without disabling foot pain at baseline    
Insufficient vitamin D (N= 91) 2.76 (1.77, 3.74) 
-1.55 (-2.76, -0.33) 0.01 
Maintaining sufficient vitamin D (N= 174) 1.21 (0.50, 1.93) 
Those with disabling foot pain at baseline    
Insufficient vitamin D (N= 23) -0.14 (-2.75, 2.48) 
-4.49 (-7.62, -1.37) 0.005 
Maintaining sufficient vitamin D (N= 52) -4.63 (-6.35, -2.92) 
Changes in outcomes are generated from mixed-effect models adjusted for age, sex, body mass index, serum 25(OH)D level and baseline MFPDI 
score. Between-group differences were calculated with maintaining sufficient vitamin D group minus insufficient group.  
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8.4 Discussion 
To the best of our knowledge, this current study is the first to investigate the effects of 
supplementing vitamin D and maintaining sufficient vitamin D level on foot pain in 
symptomatic knee OA patients. In this sample, 51.8% of participants with knee OA and vitamin 
D deficiency reported foot pain. MFPDI scores decreased more in the vitamin D treatment 
group and maintaining sufficient vitamin D group, compared to the placebo group and not 
maintain sufficient group, respectively, over 24 months. Our results suggest that foot pain is 
common and vitamin D supplementation and maintaining sufficient vitamin D levels over 24 
months may have beneficial effects on foot pain in patients with knee OA.  
Foot pain is a common condition in patients with OA. A recent cross-sectional study using data 
from the Osteoarthritis Initiative (OAI) reported that one quarter of people with knee OA 
experienced concurrent foot pain with the majority (55%) reporting pain in both feet, and knee 
OA patients with foot/ankle symptoms reported worse scores on all WOMAC subscales 
including the total score, worse health outcomes and poorer physical function compared with 
those without foot/ankle symptoms303. In our study, over half the patients (51.8%) reported 
foot pain at baseline and patients with foot pain had lower quality of life and higher rates of 
depression, which was similar to previous studies. One study reported that foot/ankle 
symptoms in either or both feet significantly increased the odds of developing knee symptoms 
and symptomatic radiographic knee OA in people at risk of the disease311. Additionally, in 
patients with symptomatic radiographic knee OA, the presence of foot/ankle symptoms was 
associated with increased risk of knee pain over four years312. Owing to the coexistent 
relationships between foot/ankle symptoms and knee OA, more attention should be paid in 
management of foot pain in OA patients. 
Although there is a growing body of evidence suggesting that a low level of vitamin D is 
associated with chronic pain, no clinical study has been conducted to explore the effect of 
vitamin D supplementation on foot pain. In addition, studies examining whether vitamin D 
supplementation is beneficial on other musculoskeletal pains are limited and found 
contradictory results167 305 313-315, mainly due to variations in participants, outcome measures, 
sample size, vitamin D dose and follow-up time. A recent secondary analysis of an RCT study 
with large sample suggested long-term monthly 100,000 IU vitamin D supplementation did not 
improve pain scores or reduce analgesic dispensing in the general population315. Similarly, a 
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Cochrane review also concluded that a large beneficial effect of vitamin D on chronic painful 
conditions across different sites was unlikely305. However, in this secondary analysis of the 
VIDEO study, we investigated the effect of vitamin D supplementation on foot pain and found 
a reduction in MFPDI scores in knee OA patients after 24 months compared with the placebo 
group, particularly in patients with disabling foot pain at baseline. There are a number of 
reasons as to why our results vary from other studies. Our participants were selected to have 
low baseline vitamin D levels, we specifically examined foot pain using a validated measure, 
our vitamin D dose was 50,000IU per month, and our duration of treatment was 2 years. Further 
clinical trials will be needed to determine whether vitamin D supplementation is beneficial for 
foot pain in patients with knee OA. Consistently, treatment with vitamin D could improve knee 
pain assessed using VAS.  However, vitamin D supplementation did not improve the knee pain 
assessed using the WOMAC scale. The reasons underlying these are unclear but may reflect 
variations in measurements. Further clinical trials are required to confirm the findings. 
Previous studies have found that low levels of vitamin D are associated with chronic pain167 172 
173, but there is no previous work linking vitamin D deficiency to foot pain. One population-
based, cross-sectional study of 958 older adults, found that a lower level of vitamin D was not 
related with foot pain, but was related with back pain316. In contrast, our study showed that 
patients who maintained vitamin D sufficiency had significantly decreased MFPDI scores 
compared with those did not maintain vitamin D sufficiency between month 3 and 24 
suggesting that correction of vitamin D deficiency might reduce foot pain over time.  
Several potential mechanisms such as bone demineralization, muscle weakness and pain 
dysregulation may link vitamin D deficiency to musculoskeletal pain. Vitamin D can modulate 
a number of inflammatory pathways317, which are associated with pain sensitization. Low 
vitamin D level can activate proinflammatory cytokine proliferation, thus alter sensitization of 
peripheral and central pathways through nociceptive inflammation processing318 319, which 
may be an important contributor to clinical symptoms of knee OA320. Even though the 
underlying mechanisms between vitamin D deficiency and foot pain are still unclear and 
further investigations are needed.  
There are several potential limitations in our study. First, this is a post hoc analysis in which 
foot pain was the secondary outcome in the original protocol. Second, nearly half of patients 
reported some foot pain at baseline, only 23.7% of patients had disabling foot pain according 
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to the definition we used in this study. Even though the MFPDI score increased less after 
vitamin D supplementation in those without disabling foot pain, the clinically significant 
difference of MFPDI score is unknown. Third, 62% of patients in placebo group reached 
sufficient vitamin D levels after 24 months’ follow-up, which might due to seasonal change, 
outdoor physical activity or other reasons that may underestimate any benefit of vitamin D. In 
support of this, beneficial effects of vitamin D were also found in MFDPI scores after patients 
were divided into consistently and not consistently sufficient vitamin D group.  
In summary, this is the first study to show that vitamin D supplementation and maintaining 
sufficient vitamin D levels reduce foot pain over two years in patients with symptomatic knee 
OA. Vitamin D supplementation and maintaining sufficient vitamin D level may improve foot 
pain in knee OA patients. 
  






Chapter 9 Summary and future directions 
OA is a highly prevalent, painful, and disabling joint disease. It is often co-existing with 
chronic comorbidities. OA has been described as “a serious disease” with no proven effective 
intervention, having significant impacts and constituting major challenges on individuals and 
public health system globally. Furthermore, co-occurrence with comorbidity in OA patients is 
also projected to increase difficulties for management and increase disease burden. Thus, the 
prevention, retarding disease progression and management of symptoms and comorbidity are 
of great importance. Identifying risk factors and management of modifiable risk factors could 
be a key for prevention and intervention. Vitamin D deficiency has been proved as a modifiable 
risk factor for OA and its comorbidity. Therefore, correcting vitamin D deficiency may have 
promising beneficial effects on OA and comorbidity. This thesis has focused on the effect of 
vitamin D on OA and comorbidity, as well as risk factors for comorbidity in OA patients. It 
has presented several novel findings from a randomised controlled clinical trial (VIDEO) in 
participants with symptomatic knee OA and vitamin D deficiency at baseline. 
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9.1 Summary of findings  
Chapter 4 is the first describing the differences in disease progression and knee symptoms 
among people with knee OA by vitamin D status over time. 340 participants who completed 
the VIDEO study were classified as consistently insufficient [serum 25(OH)D≤50nmol/l at 
month 3 and 24, n=45], fluctuating [25(OH)D>50nmol/l at either point, n=68] and consistently 
sufficient [25(OH)D>50nmol/l at month 3 and 24, n=226] vitamin D groups. The consistently 
sufficient group had significantly decreased loss of tibial cartilage volume (b: 2.1%, 95% CI: 
0.3% to 3.9%) and less increase in effusion-synovitis volume ( b: -2.5ml, 95% CI: -4.7 to -
0.2ml) compared to the consistently insufficient group in multivariable analyses. In addition, 
participants who maintained sufficient serum 25(OH)D levels over two years were associated 
with more improvement of WOMAC physical function ( b: -94.2, 95% CI, -183.8 to -4.5) than 
those with persistent vitamin D insufficiency. However, no significant differences in changes 
in cartilage defects, bone marrow lesions or knee pain between groups were found. These 
results suggest beneficial effects of maintaining vitamin D sufficiency on cartilage loss, 
effusion-synovitis and physical function in people with symptomatic knee OA.  
Low-grade systemic inflammation triggered by abnormally inflammatory or metabolic 
biomarkers has been implicated in the OA pathogenesis. Evidence has suggested vitamin D 
may modify OA disease progression through inhibition of inflammation. Chapter 5 explores 
whether vitamin D supplementation affected serum inflammatory and metabolic biomarkers 
and whether variation in vitamin D status over two years was associated with the change in 
biomarkers in patients with knee OA and vitamin D deficiency. 200 participants from one site 
(94 from placebo group and 106 from vitamin D group) from the VIDEO study were randomly 
selected for measurement of serum levels of inflammatory and metabolic biomarkers at 
baseline and 24 months. Additionally, participants were classified into two groups according 
to serum 25-hydroxyvitamin D [25(OH)D] levels at month 3 and 24: 1) not consistently 
sufficient  [25(OH)D≤50nmol/l at either month 3 or 24, N= 61], and 2) consistently sufficient 
[25(OH)D>50nmol/l at both month 3 and 24, N= 139]. Compared with placebo, monthly 
50,000 IU vitamin D supplementation had no significant effect on change in serum hs-CRP, 
IL-6, IL-8, IL-10, leptin, adiponectin, resistin, adipsin and apelin. Being consistently vitamin 
D sufficient over 2 years was also not associated with changes in these biomarkers compared 
to not being consistently sufficient. Vitamin D supplementation and maintaining vitamin D 
sufficiency did not alter serum levels of inflammatory and metabolic biomarkers over 2 years 
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in knee OA patients who were vitamin D insufficient, suggesting they may not affect systemic 
inflammation in knee OA patients.   
Depression and depressive symptoms are common among individuals with OA. The potential 
therapeutic potential of vitamin D supplementation for depression has been highlighted. 
Chapter 6 investigates the effect of vitamin D supplementation and maintaining sufficient 
serum vitamin D on depressive symptoms in patients with knee OA patients. Participants with 
symptomatic knee OA and vitamin D deficiency were enrolled in the VIDEO study and 
received 50,000IU vitamin D3 (N= 209) or placebo (N= 204) monthly for 24 months. 
Depressive symptoms were assessed using the PHQ-9 questionnaire. PHQ-9 scores improved 
more in the vitamin D treatment group (β: -0.45, 95% CI: -0.84 to -0.07) compared to the 
placebo group (β: 0.21, 95% CI: -0.19 to 0.61) (P for difference = 0.02) and  in the participants 
who maintained vitamin D sufficiency between month 3 and 24 (β: -0.44, 95% CI: -0.88 to -
0.00) compared to those who did not (β: 0.40, 95% CI: -0.18 to 0.97) (P for difference = 0.02) 
over 24 months. These findings show that vitamin D supplementation and maintaining 
adequate vitamin D levels over 24 months may be beneficial for depressive symptoms in 
patients with knee OA.   
Chapter 7 describes if the demographic and clinical factors were associated with the prevalence 
and incidence of depression and explored the temporal relationship between depression and 
joint symptoms in patients with symptomatic knee OA. The prevalence and the incidence of 
depression was 25.4% and 11.2%, respectively. At baseline, having a higher BMI, greater 
scores of WOMAC pain (PR: 1.05, 95% CI:1.03, 1.07), dysfunction (PR: 1.02, 95% CI:1.01, 
1.02) and stiffness (PR: 1.05, 95% CI: 1.02, 1.09), a lower education level, having one more 
comorbidity and having two or more site pain were significantly associated with a higher 
prevalence of depression. Over 24 months, being female, having a higher WOMAC pain (RR: 
1.04, 95% CI: 1.00, 1.08) and dysfunction score (RR: 1.01, 95% CI: 1.00, 1.02) and having 
two or more site pain were significantly associated with a higher incidence of depression. In 
contrast, baseline depression was not associated with changes in knee joint symptoms over 24 
months. Overall, knee OA risk factors and symptoms and co-existing with multi-site pain are 
associated with the prevalence and development of depression, suggesting the importance of 
managing common OA risk factors and symptoms for prevention and treatment of depression 
in patients with knee OA. 
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Chapter 8 describes the effect of vitamin D supplementation and maintaining sufficient serum 
vitamin D on foot pain in patients with knee OA patients. Foot pain severity was assessed using 
the MFPDI index. In this sample, 51.8% of participants reported they had foot pain in patients 
with knee OA and vitamin D deficiency. MFPDI scores decreased slightly in the vitamin D 
group (β: -0.03, 95% CI: -0.80 to 0.74) while worsened in the placebo group (β: 1.30, 95% CI: 
0.51 to 2.09), and there were significant differences in change of MFPDI scores between 
groups in the mixed-effect model after including all time points adjusted for age, sex and BMI 
(-0.03 in vitamin D group vs. 1.30 in placebo group; between-group difference, β: -1.32, 95% 
CI: -2.43 to -0.22, P= 0.013). Post-hoc analyses comparing participants who maintained 
sufficient vitamin D with who did not maintain vitamin D sufficiency showed similar results 
in change of MFPDI score over 2 years (2.06 in insufficient vitamin D group vs. 0.08 in 
maintaining sufficient vitamin D group; between-group difference, β: -1.98, 95%CI: -3.27 to -
0.68, P= 0.003). These suggest that vitamin D supplementation and maintaining adequate 
vitamin D levels over 24 months had beneficial effects on foot pain deterioration in OA patients.  
In summary, the findings from this thesis indicate that depression and foot pain are common 
comorbidities in patients with knee OA. Using multi-disciplinary approaches to manage 
common OA risk factors, chronic pain and joint dysfunction may be beneficial for the 
prevention and management of depression in knee OA patients. More importantly, vitamin D 
supplementation and/or maintaining vitamin D sufficiency may not affect systemic 
inflammation but may have beneficial effects on cartilage loss, effusion-synovitis, physical 
function and comorbidities including depression and foot pain in patients with knee OA. 
Recommendations for the future direction of each chapter are provided in the following. 
9.2 Future directions  
Chapter 4 uses the actual serum vitamin D levels to overcome the potentially diluting effect 
from those who achieved sufficient vitamin D levels in the placebo group during the trial. It 
has confirmed the importance of maintaining vitamin D sufficiency in symptomatic knee OA 
patients. However, for the nature of post hoc study and previous randomised controlled trials 
had some major limitations, the effect of correcting vitamin D deficiency on OA needs to be 
confirmed by further clinical trials with good designs and high quality. Adequate sample size, 
excluding participants with severe disease severity, enrolling participants with defined vitamin 
D deficiency, enough treatment duration, and using sensitive techniques to measure OA 
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outcomes are essential keys for further clinical trials147. Of importance, how to keep the vitamin 
D in low levels in the placebo group throughout the trial deserves a careful pondering. The 
Mendelian randomised studies has promising to answer this question321.  
Chapter 5 has demonstrated that vitamin D supplementation and maintaining sufficient vitamin 
D status may not have effects on systemic inflammation in knee OA patients. The reasons 
underlying these are unclear and it may also be related to the studied OA population which was 
not selected as being with an inflammatory phenotype. In another post-hoc analysis of the 
VIDEO study, we reported that vitamin D supplementation relieved the progression of 
effusion-synovitis in patients with an inflammatory OA phenotype151. These indicate that 
vitamin D supplementation would have effects on local rather than systemic inflammation in 
inflammatory OA. In future studies, the effect of vitamin D on local rather than systemic 
inflammation needs to be examined in knee OA patients with an inflammatory phenotype. 
Moreover, the potential mechanisms linking vitamin D deficiency to inflammation in the 
pathogensis of OA need to be explored further.  
Chapter 6 and 8 investigate the effect of vitamin D supplementation and maintaining vitamin 
D sufficiency on depressive symptoms and foot pain over 24 months in patients with knee OA 
and vitamin D deficiency. These results show the potentially important role of vitamin D on 
OA comorbidities. However, due to a lack of information about the clinically important 
difference for patients with milder depressive symptoms and foot pain currently, it remains 
unclear whether the statistically significant improvements in depressive symptoms and foot 
pain we reported in this study are clinically important. Therefore, more clinical studies are 
needed in the future to examine the clinical significance. Moreover, the prevalence of 
depression was 25.4% and of foot pain was 51.8% in the VIDEO sample. Further RCTs are 
required to examine the effects of depression or foot pain in patients with both knee OA and 
depression or foot pain. Most of important, why vitamin D supplementation improved foot pain 
but did not improve knee pain has to be explored and illuminated in future study. Whether 
measurement of knee pain is interference in statistically significant results and whether vitamin 
D only have beneficial effect on specific pain has to be answered.  
Chapter 7 provide empirical evidence that management of common OA risk factors, chronic 
pain and joint dysfunction may be beneficial for preventing and managing depression in knee 
OA patients. However, whether management of chronic pain and joint dysfunction has benefits 
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on depression or prevents depression occurring and whether baseline depression severity could 
moderate the intervention effects on joint symptoms are required to fully clarify. More 
importantly, having comorbidities in OA patients may contribute to increased challenges of 
treating OA patients. Therefore, treating each patient individually by a multi-disciplinary 
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